

eISBN: 978-1-68108-357-5
ISBN: 978-1-68108-358-2

eISSN: 2468-7170
ISSN: 2468-7162

OPHTHALMOLOGY
CURRENT AND FUTURE
DEVELOPMENTS (VOLUME 1)

DIAGNOSTIC ATLAS OF
RETINAL DISEASES

Editors:
Mitzy E. Torres Soriano
Gerardo García Aguirre
Maximiliano Gordon
Veronica Kon Graversen

Ophthalmology:
Current and Future Developments
Diagnostic Atlas of Retinal
Diseases
(Volume 1)

Editors

Mitzy E. Torres Soriano

*Unidad Oftalmológica "Dr. Torres López". Centro Médico
Cagua, Aragua, Venezuela*

Gerardo García Aguirre

*Retina Department,
Asociación para Evitar la Ceguera en Mexico,
Mexico City, Mexico*

Co-Editors

Maximiliano Gordon

*Centro de la Visión Gordon Manavella,
Rosario, Santa Fe, Argentina*

Veronica Kon Graversen

*University of North Carolina at Chapel Hill,
Chapel Hill, NC, USA*

Ophthalmology: Current and Future Developments

Volume # 1

Diagnostic Atlas of Retinal Diseases

Editors: Mitzy E. Torres Soriano, Gerardo García Aguirre, Maximiliano Gordon & Veronica

Kon Graversen

ISSN (Print): 2468-7162

eISSN (Online): 2468-7170

eISBN (Online): 978-1-68108-357-5

ISBN (Print): 978-1-68108-358-2

©2016, Bentham eBooks imprint.

Published by Bentham Science Publishers – Sharjah, UAE. All Rights Reserved.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.org.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it. The following DRM (Digital Rights Management) policy may also be applicable to the Work at Bentham Science Publishers’ election, acting in its sole discretion:
 - 25 ‘copy’ commands can be executed every 7 days in respect of the Work. The text selected for copying cannot extend to more than a single page. Each time a text ‘copy’ command is executed, irrespective of whether the text selection is made from within one page or from separate pages, it will be considered as a separate / individual ‘copy’ command.
 - 25 pages only from the Work can be printed every 7 days.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction,

advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of the U.A.E. as applied in the Emirate of Dubai. Each party agrees that the courts of the Emirate of Dubai shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.
3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Ltd.

Executive Suite Y - 2

PO Box 7917, Saif Zone

Sharjah, U.A.E.

Email: subscriptions@benthamscience.org



CONTENTS

FOREWORD	i
PREFACE	ii
ACKNOWLEDGEMENTS	ii
DEDICATION	ii
LIST OF CONTRIBUTORS	iv
CHAPTER 1 NON-PROLIFERATIVE DIABETIC RETINOPATHY	3
<i>Nwku'Hgkr g'Tkxgt q'cpf 'Oczko kkc pq' T qtf qp</i>	
ESSENTIALS OF DIAGNOSIS	3
Classification	12
DIFFERENTIAL DIAGNOSIS	13
MANAGEMENT	15
CONFLICT OF INTEREST	15
ACKNOWLEDGEMENTS	15
REFERENCES	15
CHAPTER 2 PROLIFERATIVE DIABETIC RETINOPATHY (PDR)	18
<i>O ctkc 'J ODgt t qecrkcpf 'Nwku'CO'ced^a</i>	
ESSENTIALS OF DIAGNOSIS	18
DIFFERENTIAL DIAGNOSIS	18
MANAGEMENT	23
CONFLICT OF INTEREST	28
ACKNOWLEDGEMENTS	28
REFERENCES	28
CHAPTER 3 DIABETIC MACULAR EDEMA	29
<i>O czko kkc pq' T qtf qp' c'pf 'Okj / 'GOVqt t gu'Uqt k'pq</i>	
ESSENTIALS OF DIAGNOSIS	29
DIFFERENTIAL DIAGNOSIS	39
MANAGEMENT	40
CONFLICT OF INTEREST	42
ACKNOWLEDGEMENTS	42
REFERENCES	42
CHAPTER 4 CENTRAL RETINAL VEIN OCCLUSION	44
<i>P gnuqp 'Ugi qxc 'Tqft f' wgl</i>	
ESSENTIALS OF DIAGNOSIS	44
DIFFERENTIAL DIAGNOSIS	53
MANAGEMENT	53
CONFLICT OF INTEREST	55
ACKNOWLEDGEMENTS	55
REFERENCES	55
CHAPTER 5 BRANCH RETINAL VEIN OCCLUSION	58
<i>Nk kcp / 'Crt kgc 'Tvkj 'cpf 'I gctcf q' I cte'f' Ci wkt g</i>	
ESSENTIALS OF DIAGNOSIS	58
DIFFERENTIAL DIAGNOSIS	64
MANAGEMENT	64
CONFLICT OF INTEREST	65
ACKNOWLEDGEMENTS	65
REFERENCES	66

CHAPTER 6 A THREE-DIMENSIONAL LOOK INTO HYPERTENSIVE RETINOPATHY	67
<i>Tchl'grl'Owek'O gpf q/c</i>	
ESSENTIALS OF DIAGNOSIS	67
Complications of Hypertensive Retinopathy	73
Classification	73
DIFFERENTIAL DIAGNOSIS	74
MANAGEMENT	80
CONFLICT OF INTEREST	80
ACKNOWLEDGEMENTS	80
REFERENCES	80
CHAPTER 7 CENTRAL RETINAL ARTERY OCCLUSION	82
<i>Ukkl'e'O gpf q/c. 'Uk'pft'e' \ co dtcpq. 'F kgi q'Hgtpepf q'O qlk'ec'cpf 'O k'/'GOVqt t gu'Uqt kcpq</i>	
ESSENTIALS OF DIAGNOSIS	83
Symptoms	83
Fundus Findings	83
Complementary Exams	84
DIFFERENTIAL DIAGNOSIS	87
MANAGEMENT	88
CONFLICT OF INTEREST	88
ACKNOWLEDGEMENTS	89
REFERENCES	89
CHAPTER 8 BRANCH RETINAL ARTERY OCCLUSION AND CILIORETINAL ARTERY OCCLUSION	90
<i>Tcwl'Xgg//O qpvq/c</i>	
ESSENTIALS OF DIAGNOSIS	91
DIFFERENTIAL DIAGNOSIS	95
MANAGEMENT	95
CONFLICT OF INTEREST	96
ACKNOWLEDGEMENTS	96
REFERENCES	96
CHAPTER 9 RETINAL ARTERIAL MACROANEURYSM	99
<i>Tqf tki q'Ngej wi c'Rgt gl'cpvc'cpf 'Xki ktk'q'O qt'cngu'Ecpv»p</i>	
ESSENTIALS OF DIAGNOSIS	100
DIFFERENTIAL DIAGNOSIS	104
MANAGEMENT	104
CONFLICT OF INTEREST	105
ACKNOWLEDGEMENTS	105
REFERENCES	105
CHAPTER 10 MACULAR TELANGIECTASIA	107
<i>[qi kp'Revgrl'cpf 'Ok'ej cgrl'FOQdgt</i>	
ESSENTIALS OF DIAGNOSIS	107
DIFFERENTIAL DIAGNOSIS	113
MANAGEMENT	114
CONFLICT OF INTEREST	114
ACKNOWLEDGEMENTS	114
REFERENCES	114
CHAPTER 11 SICKLE CELL RETINOPATHY	116
<i>Nwng'DONkpf ugnl'cpf 'C/k'COMj cplkt</i>	
ESSENTIALS OF DIAGNOSIS	116
DIFFERENTIAL DIAGNOSIS	121
MANAGEMENT	122

CONFLICT OF INTEREST	123
ACKNOWLEDGEMENTS	123
REFERENCES	123
CHAPTER 12 RADIATION RETINOPATHY	125
<i>Xgt qpkc 'Mqp' T t cxgtugp</i>	
ESSENTIALS OF DIAGNOSIS	125
DIFFERENTIAL DIAGNOSIS	127
MANAGEMENT	127
CONFLICT OF INTEREST	128
ACKNOWLEDGEMENTS	128
REFERENCES	128
CHAPTER 13 OCULAR ISCHEMIC SYNDROME	130
<i>Grgpqt c 'Ncxcs wg</i>	
ESSENTIALS OF DIAGNOSIS	130
DIFFERENTIAL DIAGNOSIS	134
MANAGEMENT	134
CONFLICT OF INTEREST	135
ACKNOWLEDGEMENTS	135
REFERENCES	135
CHAPTER 14 DRY AGE-RELATED MACULAR DEGENERATION	136
<i>Cpc 'Fqo 'pi wgl' T cvgu'cpl 'Xki ki'Crctq</i>	
ESSENTIALS OF DIAGNOSIS	136
DIFFERENTIAL DIAGNOSIS	158
MANAGEMENT	164
CONFLICT OF INTEREST	164
ACKNOWLEDGEMENTS	164
REFERENCES	164
CHAPTER 15 WET AGE-RELATED MACULAR DEGENERATION	168
<i>I gtctfq' T cte'c/Ci wktg</i>	
ESSENTIALS OF DIAGNOSIS	168
DIFFERENTIAL DIAGNOSIS	182
MANAGEMENT	182
CONFLICT OF INTEREST	184
ACKNOWLEDGEMENTS	184
REFERENCES	184
CHAPTER 16 POLYPOIDAL CHOROIDAL VASCULOPATHY	186
<i>Lepu'Htqo qy 'T wgttc</i>	
ESSENTIALS OF DIAGNOSIS	186
Epidemiology Essentials of PCV	186
Clinical Essentials of PCV	187
DIFFERENTIAL DIAGNOSIS	190
MANAGEMENT	190
CONFLICT OF INTEREST	191
ACKNOWLEDGEMENTS	191
REFERENCES	191
CHAPTER 17 RETINAL ANGIOMATOUS PROLIFERATION (RAP)	193
<i>Oczko hkepq' T qtf qp</i>	
ESSENTIALS OF DIAGNOSIS	193
DIFFERENTIAL DIAGNOSIS	194
MANAGEMENT	196
CONFLICT OF INTEREST	198

ACKNOWLEDGEMENTS	198
REFERENCES	198
CHAPTER 18 CHOROIDAL NEOVASCULAR MEMBRANE IN DEGENERATIVE MYOPIA	201
<i>Hgf gtlkq'Hwt pq'Uqrc</i>	
ESSENTIALS OF DIAGNOSIS	201
DIFFERENTIAL DIAGNOSIS	205
MANAGEMENT	206
CONFLICT OF INTEREST	206
ACKNOWLEDGEMENTS	206
REFERENCES	206
CHAPTER 19 ANGIOID STREAKS	207
<i>Olej cgrlNctugp.'O gwg'MOI 0Cpf gtugp.'Pct guj 'Ocpf cxc'cpi 'Tlej ctf 'J y cpi</i>	
ESSENTIALS OF DIAGNOSIS	211
DIFFERENTIAL DIAGNOSIS	216
MANAGEMENT	216
CONFLICT OF INTEREST	217
ACKNOWLEDGEMENTS	217
REFERENCES	217
CHAPTER 20 PRESUMED OCULAR HISTOPLASMOSIS SYNDROME	219
<i>OcpwgrlI ct c/Ng»p.'Nw 'Grgpc'Eqpej c'f grlT'q'cpi 'Oki wgrlRgf tq c'Ugt gu</i>	
ESSENTIALS OF DIAGNOSIS	219
DIFFERENTIAL DIAGNOSIS	223
MANAGEMENT	224
CONFLICT OF INTEREST	224
ACKNOWLEDGEMENTS	224
REFERENCES	225
CHAPTER 21 EPIRETINAL MEMBRANE	227
<i>Ci kankf gu'L00 gpf q c'R0</i>	
ESSENTIALS OF DIAGNOSIS	228
DIFFERENTIAL DIAGNOSIS	231
MANAGEMENT	232
CONFLICT OF INTEREST	232
ACKNOWLEDGEMENTS	232
REFERENCES	232
CHAPTER 22 IDIOPHATIC MACULAR HOLE	234
<i>Nwul'O0Uwct g Vcx.'O qt cxc'D0Uwct g Vcx'cpi 'Tgkpcif q'I cte'f</i>	
ESSENTIALS OF DIAGNOSIS	234
Classification	235
DIFFERENTIAL DIAGNOSIS	235
MANAGEMENT	246
CONFLICT OF INTEREST	246
ACKNOWLEDGEMENTS	246
REFERENCES	246
CHAPTER 23 MACULAR PSEUDO-HOLE	248
<i>Lqug'C0Tqec.'J wi q'Nwi riq'cpi 'F cplgr' Tqec</i>	
ESSENTIALS OF DIAGNOSIS	248
DIFFERENTIAL DIAGNOSIS	251
MANAGEMENT	252
CONFLICT OF INTEREST	252
ACKNOWLEDGEMENTS	252
REFERENCES	252

CHAPTER 24 VITREOMACULAR TRACTION	254
<i>O k\j /'G0Vqtt gu'Uqt kcpq'cpf 'Oczko k kcpq'T qtf qp</i>	
ESSENTIALS OF DIAGNOSIS	254
DIFFERENTIAL DIAGNOSIS	258
MANAGEMENT	258
CONFLICT OF INTEREST	259
ACKNOWLEDGEMENTS	259
REFERENCES	259
CHAPTER 25 PSEUDOPHAKIC CYSTOID MACULAR EDEMA	261
<i>Cpf t² u'Dc:wkgp</i>	
ESSENTIALS OF DIAGNOSIS	261
Pathogenesis	261
Incidence and Risk Factors	264
DIFFERENTIAL DIAGNOSIS	265
MANAGEMENT	268
CONFLICT OF INTEREST	272
ACKNOWLEDGEMENTS	272
REFERENCES	272
CHAPTER 26 CENTRAL SEROUS CHORIORETINOPATHY	277
<i>F cplgtF 0Mko . 'RcwtDcekw 'OF 'cpf 'Okej cgnF 0Qdgt</i>	
ESSENTIALS OF DIAGNOSIS	277
DIFFERENTIAL DIAGNOSIS	281
MANAGEMENT	281
CONFLICT OF INTEREST	283
ACKNOWLEDGEMENTS	283
REFERENCES	283
SUBJECT INDEX	286

FOREWORD

Drs. Torres, García, Gordon and Kon deliver a very useful and practical work that contains, in this volume, a collection of images of retinal vascular diseases and macular diseases. The editors have recruited a vast array of retina specialists from four continents to write the different chapters that constitute this volume. The chapters are structured in such a way that the reader may easily find pearls about the diagnosis, differential and treatment, accompanied by beautiful pictures using different imaging modalities. Our subspecialty has had tremendous advances in recent years regarding diagnostic imaging, and I'm sure ophthalmologists and residents will find this compilation really useful and enjoyable.

Dr. Hugo Quiroz-Mercado

Retina Department

Asociación para evitar la Ceguera en Mexico

Mexico City

Mexico

E-mail: hugoquiroz@yahoo.com

PREFACE

We are honored to contribute to the information and education of ophthalmology students around the world. We have attempted to distill the current knowledge of medical practice and basic science retina research into a diagnostic atlas of retinal diseases. This is a quick-reference atlas eBook of the retina, edited by specialists in the field, essential to any practicing ophthalmologist or resident who has more than a passing interest in diseases and treatment of the retina.

This e-book includes contributors from Mexico, Venezuela, Argentina, Brazil, United States, Denmark, Spain, Italy, Costa Rica and Peru. It is divided into three volumes: Volume I, retinal vascular diseases, choroidal neovascularization related diseases, vitreomacular interface, and other macular disorders; Volume II, traumatic retinopathies, diseases of vitreous, peripheral degenerations, retinal detachment, pediatric retinal diseases, and retinal dystrophies; and Volume III, posterior uveitis, tumors of the retina, and choroid.

This diagnostic atlas eBook of retinal diseases contains full-color, high quality images of the most frequent retinal pathologies with a brief and comprehensive review of retinal diseases. Each chapter includes essentials of diagnosis, differential diagnosis and treatment. The format is concise, well organized, and didactic, without being exhaustive.

We hope and expect that our atlas of retina will facilitate in providing patients with the best possible care.

ACKNOWLEDGEMENTS

We would like to express our gratitude to Judy Soriano, who provided support with english composition and edition.

To our friends and colleagues without whose contribution would not have been possible to realize this project.

We also want to thank the staff of Bentham Science for their help and support and give us the opportunity to publish this eBook.

DEDICATION

This e-book is specially dedicated to Guillermo Manuel Gordon, MD. He inspired us to always work hard and try our best. He was a friend and a recognized ophthalmologist of Rosario-Argentina, who died on May 2nd, 2015.

Dr. Mitzy E. Torres Soriano
Unidad Oftalmológica “Dr. Torres López”,
Centro Médico Cagua,
Aragua,
Venezuela

Dr. Gerardo García Aguirre
Retina Department,
Asociación para Evitar la Ceguera en Mexico,
Mexico City,
Mexico

Dr. Maximiliano Gordon
Centro de la Visión Gordon Manavella,
Rosario, Santa Fe,
Argentina

Dr. Veronica Kon Graversen
University of North Carolina at Chapel Hill,
Chapel Hill, NC,
USA

List of Contributors

Andrés Bastien	Universidad de Buenos Aires-Universidad del Salvador, Retina and Vitreous, Argentina
Aristides J. Mendoza	Retina Department, Centro Oftalmológico de Valencia (CEOVAL), Valencia, Venezuela Retina Department, OftalmoSalud, Arequipa, Peru
Ana Domínguez Yates	Retina Consultants of Charleston, Charleston, South Carolina, USA
Aziz A. Khanifar	Retina Group of Washington, Washington DC, USA
Daniela Roca	Ophthalmology Department, Clínica Ricardo Palma, Lima, Peru
Diego Fernando Mojica	Centro Oftalmológico de Valencia (CEOVAL), Valencia, Venezuela
Daniel D. Kim	Department of Ophthalmology, Henry Ford Health Systems, Detroit, MI, USA
Eleonora Lavaque	Retina Deparment, Hospital Oftalmológico Santa Lucía, Buenos Aires, Argentina
Federico Furno Sola	Ophthalmology Service, Sanatorio Mapaci, Rosario, Argentina Grupo Laser Visión, Rosario, Santa Fe, Argentina
Gerardo García Aguirre	Retina Department, Asociación para Evitar la Ceguera en Mexico, Mexico City, Mexico
Guillermo Gordon	Died
Hugo Luglio	Macula D&T, Lima, Peru
Jans Fromow Guerra	Retina Department, Asociación para Evitar la Ceguera en México, IAP, México City, México
Jose A. Roca	Ophthalmology Department, Clínica Ricardo Palma, Lima, Peru
Luis Felipe Rivero	Centro Clínico, de Ojos Maracay, Maracay, Venezuela Centro Oftalmológico Regional Aragua “Filippo Sindoni”, Maracay, Venezuela
Luis A. Acabá	Sidney Kimmel College of Medicine, Philadelphia, PA, USA
Liriany Arrieta Ruiz	Unidad Popular de Ojos (UPO), Maracay, Venezuela
Luke B. Lindsell	Retina Group of Washington, Washington DC, USA
Luz Elena Concha del Río	Uveitis Department, Asociación para Evitar la Ceguera en México. I.A.P, Mexico
Luis M. Suarez-Tata	Retina & Vitreous Service, Clínica Oftalmológica El Viñedo, Valencia, Venezuela

Maximiliano Gordon	Centro de la Visión Gordon-Manavella, Rosario, Santa Fe, Argentina
Maria H. Berrocal	Berrocal & Asociados, San Juan, Puerto Rico
Mitzy E. Torres Soriano	Centro de la Visión Gordon-Manavella, Rosario, Santa Fe, Argentina Unidad Oftalmológica “Dr Torres López”, Centro Médico Cagua, Aragua, Venezuela
Michael D. Ober	Department of Ophthalmology, Henry Ford Health System, Detroit, MI, USA Retina Consultants of Michigan, Southfield, MI, USA
Michael Larsen	Department of Ophthalmology, Glostrup Hospital and Faculty of Health Sciences, University of Copenhagen, Denmark
Mette K.G. Andersen	Department of Ophthalmology, Glostrup Hospital and Faculty of Health Sciences, University of Copenhagen, Denmark
Manuel Garza León	Department of Medical Sciences, Division of Health Sciences, Universidad de Monterrey, Monterrey, Nuevo León, México
Miguel Pedroza Seres	Uveitis and Ocular Immunology Department, Instituto de Oftalmología Conde de Valenciana, México, DF. Clínica de Retina, Guadalajara, Jalisco, Mexico
Moravia B. Suarez-Tata	Retina & Vitreous Service, Clínica Oftalmológica El Viñedo, Valencia, Venezuela
Naresh Mandava	Department of Ophthalmology, University of Colorado School of Medicine, Aurora, CO, USA
Nelson Segovia Rodríguez	Retina Department, Grupo de Clínicas IDB, Centro Profesional Arca, Barquisimeto, Venezuela
Paul Baci	Department of Ophthalmology, Henry Ford Health Systems, Detroit, MI, USA
Raul Velez-Montoya	Retina Department, Asociación para Evitar la Ceguera en México, IAP, Mexico City, Mexico
Rafael Muci Mendoza	Universidad Central de Venezuela, Unidad de Neurooftalmología, Hospital Vargas de Caracas, Venezuela
Rodrigo Lechuga Perezanta	Asociación para Evitar la Ceguera en Mexico, Mexico City, Mexico
Richard Hwang	Vitreoretinal Disease and Surgery, Department of Ophthalmology, University of Colorado School of Medicine, Aurora, CO, USA
Reinaldo García	Retina & Vitreous Service, Clínica Oftalmológica El Viñedo, Valencia, Venezuela
Silvia Mendoza	Retina Department, Centro Oftalmológico de Valencia (CEOVAL), Valencia, Venezuela

vi

Sandra Zambrano	Centro Oftalmológico de Valencia (CEOVAL), Valencia, Venezuela
Virgilio Morales Cantón	Retina Department, Asociación para Evitar la Ceguera en Mexico, Mexico City, Mexico
Veronica Kon Graversen	University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Virgil Alfaro	Retina Consultants of Charleston, Charleston, South Carolina, USA
Yogin Patel	Department of Ophthalmology, Henry Ford Health System, Detroit, MI, USA

Non-Proliferative Diabetic Retinopathy

Luis Felipe Rivero^{1,2,*} and Maximiliano Gordon³

¹ *Centro Clínico de Ojos Maracay, Maracay, Venezuela*

² *Centro Oftalmológico Regional Aragua “Filippo Sindoni”, Maracay, Venezuela*

³ *Centro de la Visión Gordon-Manavella, Rosario, Santa Fe, Argentina*

Diabetic retinopathy (DR) is the most frequent ocular complication in patients with diabetes mellitus. Its early and moderate stages are called non-proliferative diabetic retinopathy (NPDR). It is characterized clinically by the presence of one or more of the following signs: microaneurysms, intraretinal hemorrhages, intraretinal microvascular anomalies (IRMA), cotton-wool spots (CWS), hard exudates, and venous beading.

ESSENTIALS OF DIAGNOSIS

The hallmark of DR is the development of microaneurysms, which are small dilations of the capillaries due to weakening of their walls and the loss of pericytes [1]. They appear clinically as tiny red dots in the retinal stroma, predominantly in and around the posterior pole. Eventually they may break, leading to the formation of intraretinal hemorrhages. When the broken microaneurysms are located in the most superficial layers of the retina, the hemorrhage will take a flame or splinter-like appearance, oriented along the nerve fiber layer. When they are located in the deeper layers, the hemorrhage will look like a red dot or blot. Clinically, microaneurysms and dot hemorrhages are indistinguishable (Fig. 1), so they are referred to as hemorrhages and/or microaneurysms (H/Ma). Unless clotted, microaneurysms will show as hyperfluorescent points in a fluorescein angiogram (FA). They may or may not

* **Corresponding author Luis Felipe Rivero:** Centro Clínico de Ojos Maracay, Av. José María Vargas N° 18, Maracay 2101, Edo. Aragua, Venezuela; Tel: +58(243) 241-8324/5243; E-mail: luife2020@hotmail.com

leak dye depending on the integrity of their walls (Fig. 2). In an optic coherence tomography (OCT), they appear as hyperreflective rings usually located in the middle retinal layers [2] (Fig. 3). The smaller intraretinal hemorrhages will hardly show in the FA, while the larger ones block the dye (Fig. 4). The largest intraretinal hemorrhages may be seen in an OCT as moderately hyperreflective masses located in the inner retinal layers.




Fig. (1). Intraretinal hemorrhages and microaneurysms. **Left:** Both deep intraretinal hemorrhages and microaneurysms (H/Ma) appear as small red points and dots. Some of them are pointed with arrows. **Right:** Superficial intraretinal hemorrhages have a splinter or flame shape (some of them are pointed with arrows). Note that superficial hemorrhages as well as CWS follow the striations of the nerve fiber layer.

Capillary wall damage will lead to leakage of fluids and macromolecules. These will accumulate in the retinal stroma producing macular edema, which can be observed as areas of thickening of the retina. Lipoproteins diffusing from microaneurysms or weakened capillaries will be trapped at the outer plexiform layer forming the so-called hard exudates. They are irregularly shaped yellow-white spots located slightly deeper in the retina and may coalesce with each other, forming streaks, clusters or a circinate pattern centered on the leaking structure (Fig. 5). They may accumulate in the center of the fovea forming a dense plaque, which carries a very bad visual prognosis [3]. They are not usually seen on a FA, except when they are extremely dense, causing minimum blockage of the dye. On the OCT they appear as markedly hyperreflective and irregular interstitial images with posterior shadowing (Fig. 6).




Fig. (2). Fluorescein angiogram showing microaneurysms. They can be observed as well-defined hyper-fluorescent (white) dots, appearing in the early phases of the study. Non-leaking microaneurysms will remain as well-defined dots throughout the angiogram (some are circled in red). Leaking microaneurysms develop a hazy area around them that increases along the study (some are circled in yellow).

As diabetic retinopathy progresses, there will be further damage to the arterioles and capillaries, leading to progressive ischemia. Focal ischemia in the inner layers will result in the arrest of the axoplasmic flow with the subsequent dilation of the axons, constituting the so-called CWS [4]. Clinically they present as small superficial grey-white fluffy spots with feathery borders (Fig. 7). They are usually located near the temporal arcades and near the disc in the nasal retina. They look hypofluorescent in the FA (Fig. 4). In an OCT they appear as more or less pronounced focal thickenings of the nerve fiber layer with enhanced hyperreflectivity (Fig. 8). Over some 6 to 12 months CWS will eventually fade, leaving almost no signs of their former presence but relative scotomata [5] and nicks in the inner retinal layers [6].

Proliferative Diabetic Retinopathy (PDR)

Maria H. Berrocal^{1,*} and Luis A. Acabá²

¹ *Berrocal & Asociados, San Juan, Puerto Rico*

² *Sidney Kimmel College of Medicine, Philadelphia, PA, USA*

ESSENTIALS OF DIAGNOSIS

Proliferative diabetic retinopathy (PDR) occurs as a progression of severe diabetic vascular damage and includes intraretinal capillary closure with resultant ischemia and the formation of new vessels (Figs. 1-3). Severe non-proliferative diabetic retinopathy is the precursor of PDR. It includes diffuse intraretinal hemorrhages in 4 quadrants, venous beading in 2 quadrants or more and intra-retinal microvascular abnormalities (IRMA) in 1 quadrant. The chance of progression to PDR in 1 year is between 15% and 45% [1, 2].

Severe NPDR can be confused with PDR. Fluorescein angiography is the best way to differentiate IRMA from neovascularization as the latter shows significant leakage throughout the study. The evolution of new vessels starts with fine vessels with minimal fibrosis, then an increase in vessel size and fibrous tissue, and then the end stage of PDR which includes regressed vessels and significant fibrovascular proliferation on the posterior hyaloid. Vitreous hemorrhage and sub-hyaloid hemorrhage can result from PDR.

DIFFERENTIAL DIAGNOSIS

Differential diagnosis includes NPDR particularly when many IRMAs are present, other retinovascular diseases like vein occlusions, sickle cell retinopathy,

* **Corresponding author Maria H. Berrocal:** 150 Ave De Diego Ste 404, San Juan, 00907, Puerto Rico; Tel: (787) 725-9315; E-mail: mariaherrocal@hotmail.com

leukemic retinopathy, hypertensive retinopathy, radiation retinopathy, retinal vasculitis, sarcoidosis, and ocular ischemic syndrome. Differences in the clinical picture and fluorescein angiographic appearance are usually sufficient to discriminate between these entities.




Fig. (1). A. Red-free image of the right eye of a 35 year-old male with prominent neovascularization in the posterior pole; B. Red-free image of the left eye in the same patient, showing neovascularization and exudates.




Fig. (2-I). 66-year-old male with type 1 diabetes mellitus and proliferative diabetic retinopathy. **A.** Early fluorescein angiography (FA) of the right eye showing multiple areas of capillary dropout and ischemia, including the foveal area with enlarged foveal avascular zone. One area of NVE is present in the superotemporal arcade; **B.** FA of the nasal retina with severe ischemia and capillary leakage; **C.** Late FA of the same eye, showing diffused leakage in the posterior pole; **D.** OCT of retinal area near neovascularization showing areas of localized tractional retinal detachment.

Diabetic Macular Edema

Maximiliano Gordon^{1,2,*} and Mitzy E. Torres Soriano^{1,2,3}

¹ *Centro de la Visión Gordon-Manavella, Rosario, Santa Fe, Argentina*

² *Retina Department, Ophthalmology Service, Hospital Provincial del Centenario, Rosario, Santa Fe, Argentina*

³ *Unidad Oftalmológica “Dr Torres López”, Centro Médico Cagua, Aragua, Venezuela*

Diabetic macular edema (DME) is the main cause of visual loss in diabetic patients. It may present at every stage of diabetic retinopathy.

The systemic risk factors identified for DME are hyperglycemia, arterial hypertension, hyperlipidemia, kidney failure and anemia [1, 2].

ESSENTIALS OF DIAGNOSIS

Diabetic macular edema is diagnosed with a detailed bio-microscopic examination with the slit lamp and indirect ophthalmoscopy.

The Early Treatment Diabetic Retinopathy Study (ETDRS) described DME as retinal thickening or hard exudates (consisting of lipoproteins) within 1 disk diameter of the center of the macula (Figs. **1, 2, 4a, 5a-b, 6a, 8, 11a**).

The term clinically significant macular edema (CSME) indicates the severity of macular edema and is used for treatment guidelines. CSME is characterized by: 1) thickening of the retina within 500 μm of the macular center; 2) hard exudates at the center of the retina or within 500 μm with thickening of adjacent retina; and 3) one or more disc diameters of retinal thickening, part of which is within one disc diameter of the center of the macula [3].

* **Corresponding author Maximiliano Gordon:** Centro de la Vision Gordon - Manavella, Montevideo 763, CP 2000, Rosario - Santa Fe, Argentina; Tel: +54 (0341) 4 400 239; E-mail: maximilianogordon19@gmail.com



Fig. (1). Fundus photograph of CSME in both eyes. Microaneurysms, hard exudates and retinal hemorrhages are shown.



Fig. (2). Fundus photograph of severe and clinically significant diabetic macular edema in both eyes.

In 2002, the American Academy of Ophthalmology proposed an international classification of DME (Table 1): DME absent: absence of retinal thickening or hard exudates in the posterior pole. DME present: some retinal thickening or hard exudates in the posterior pole.

Table 1. International clinical diabetic macular edema (DME) disease severity scale.

Proposed Disease Severity Level	Findings observable on Dilated Ophthalmoscopy
Mild DME	Some retinal thickening or hard exudates in posterior pole but far from the macula center
Moderate DME	Retinal thickening or hard exudates that approach the macular center but without involving it
Severe DME	Retinal thickening or hard exudates involving the macula center

Program and abstracts of the American Academy of Ophthalmology 2002 [4].

Classically, three different types of DME can be observed in fluorescein angiography (FA): 1) focal leakage: well-defined focal area of leakage from micro-aneurysms or dilated capillaries (Figs. 3-6); 2) diffuse leakage: widespread leakage from IRMA, retinal capillary bed (Fig. 7); and 3) diffuse cystoid leakage: diffuse leakage and pooling of dye in the cystic spaces of the macula in the late phase of the angiogram [5]. However, one of the most important utilities of the angiography is to roll out macular ischemia (Fig. 7). It has long been considered that ischemic changes and microvascular pathologies are key in the development of DME. In diabetic retinopathy, peripheral ischemia leads to an increased production of vascular endothelial growth factor (VEGF), which can result in the breakdown of blood-retinal barriers, thus increasing retinal vessel permeability and causing DME. These areas can be detected using ultra-wide field fluorescein angiography [6].




Fig. (3). FA of the same patient as shown in Fig. (1). (a-b) Multiple hyperfluorescent points due to microaneurysms with mild leakage in late phases (c-d).

Central Retinal Vein Occlusion

Nelson Segovia Rodríguez*

Retina Department, Grupo de Clínicas IDB, Centro Profesional Arca, Barquisimeto, Venezuela

Central retinal vein occlusion (CRVO), a member of the group of vascular retinal diseases, is a sight-threatening condition that needs to be correctly diagnosed and treated in order to diminish its consequences, which can lead to painful blindness if neovascular glaucoma (NVG) develops. CRVO occurs predominantly in adults of 65 years old and over [1]; the prevalence does not differ by gender [2], and it is predominantly unilateral [3]. Some described systemic risk factors are end-organ damage from hypertension or diabetes, a hypercoagulable state, and a diagnosis of stroke or obstructive sleep apnea [4, 5]. The most described ocular risk factor is glaucoma. Patients with CRVO also show an increased (almost two-fold) incidence in cerebrovascular accidents compared with age and sex-matched controls in a US population [6].

ESSENTIALS OF DIAGNOSIS

Fortunately, this is a relatively easy condition to diagnose based mostly on its clinical features. CRVO commonly presents as a sudden and painless loss of vision. Occasionally, the vision loss occurs gradually, mostly happens at night time in the recumbent position probably by low blood pressure and/or high central venous pressure. The typical fundoscopic features appear in all the four quadrants of the fundus: venous tortuosity and dilation, retinal hemorrhages (scattered superficial and deep), and cotton wool spots (Figs. 1-3). Macular edema and optic disc swelling are also present. All these features are present in varying degrees depending on the severity of the occlusion. Long-standing CRVO should be

* Corresponding author Nelson Segovia Rodríguez: Retina Department, Grupo de Clínicas IDB, Centro Profesional Arca, Barquisimeto, Venezuela; Tel: +57(315)5929618; Email: nelsegovia@yahoo.com

suspected if occluded or sheathed retinal veins are observed, or if vascular anastomoses (known as optociliary collaterals) at the optic disc are detected (Fig. 4).




Fig. (1). Central Retinal Vein Occlusion. Fundus photograph shows tortuosity and dilatation of all branches of the central retinal vein, dot and flame-shaped hemorrhages, macular edema and optic nerve head cupping is noted. (Courtesy of Mitzy E. Torres Soriano).




Fig. (2). Fundus photograph showing massive intraretinal hemorrhages, venular tortuosity, cotton wool spots and macular edema, corresponding to an ischemic CRVO.




Fig. (3). Red-free photograph shows the typical features of CRVO, corresponding to a non-ischemic CRVO.



Fig. (4). Eye fundus of a patient with long standing CRVO demonstrating optociliary shunts vessels (optociliary collaterals) in the optic nerve head, and panretinal photocoagulation.

CRVO can be divided into 2 clinical types, ischemic and non-ischemic. Non-ischemic CRVO (Figs. 3, 5, 6) is the most common type, accounting for about 75% CRVO cases. Non-ischemic CRVO is characterized by mild to moderate loss of acuity, usually 20/200 or better, and an absent or mild relative afferent pupillary defect. Conversion to ischemic CRVO occurs in 15% of cases within 4

Branch Retinal Vein Occlusion

Liriany Arrieta Ruiz¹ and Gerardo García Aguirre^{2,*}

¹ *Unidad Popular de Ojos (UPO), Maracay, Venezuela*

² *Retina Department, Asociación para Evitar la Ceguera en Mexico, Mexico City, Mexico*

Branch Retinal Vein Occlusion (BRVO) is a common retinal vascular disease caused by the occlusion of one of the branches of the central retinal vein, affecting only a portion, typically a quadrant, of the posterior pole [1]. It is three times more common than the central retinal vein occlusion, and onset usually occurs in the elderly. There are some risks factors for its development: hypertension, cardiovascular disease, obesity and open angle glaucoma.

ESSENTIALS OF DIAGNOSIS

Patients usually complain of a sudden onset of blurred vision or central visual field defect.

Upon ophthalmologic examination, typical findings include superficial hemorrhages, which are usually flame-shaped, retinal edema, and cotton-wool spots in a sector of retina drained by the affected vein (Figs. 1-3). The horizontal raphe is respected.

In the chronic stage (Fig. 4), hemorrhages may be absent and macular edema with telangiectatic vessels can be observed, extending across the horizontal raphe. The quadrant most commonly affected is the superotemporal (63%) [2].

* **Corresponding author Gerardo García Aguirre:** Retina Department, Asociación para Evitar la Ceguera en Mexico, Vicente García Torres 46, San Lucas Coyoacan, Mexico City 04030, Mexico; Tel: +52 (55) 10841400; Email: jerry_gar_md@yahoo.com



Fig. (1). Flamed-shaped hemorrhages and retinal edema in superior macular area. (Courtesy of Gerardo Garcia Aguirre (Mexico)).



Fig. (2). Retinal hemorrhages, cotton-wool spots and sclerotic vessels in inferotemporal BRVO. (Courtesy of Gerardo Garcia Aguirre (Mexico)).




Fig. (3). Intraretinal hemorrhages in the superotemporal area and macular edema. (Courtesy of Gerardo García Aguirre (Mexico)).



Fig. (4). Left eye: Chronic superior temporal branch retinal vein occlusion, sclerotic vessels and neovascularization. Courtesy of Luis Miguel Suarez Tata MD (Venezuela).

A Three-Dimensional Look into Hypertensive Retinopathy

Rafael Muci Mendoza*

Universidad Central de Venezuela, Unidad de Neurooftalmología, Hospital Vargas de Caracas, Venezuela

ESSENTIALS OF DIAGNOSIS

The amount of arteriolar damage signals the individual prognosis of a hypertensive subject; therefore, any information about its severity will be extremely helpful in a practical way. Arteriolosclerosis is the hardening and narrowing of the arterioles secondary to systemic arterial hypertension [1]. Fundoscopic changes reflect the duration, severity, and the right way to control hypertension, so monitoring the changes in the retina, the choroid, and the optic nerve will help the physician determine the best course of care of the hypertensive patient. “Essential” or “primary” hypertension is a pathological condition characterized by endothelial dysfunction that affects vessel structure and tone, thus causing constriction of blood vessels and narrowing of small arteries and arterioles in the peripheral vascular bed. It is a silent disease and its injurious effect begins many years before organic damage becomes clinically apparent [2, 3]. Arteriosclerosis follows chronic arterial hypertension like a shadow [4]. The amount of arteriolar damage is the essential piece of information that signals the individual prognosis of a hypertensive subject [5, 6]. Retinal arterioles share similar anatomical, physiological and embryological characteristics with cerebral, coronary and renal arterioles. Thus, the ocular fundus and the retina are like doors open to medical curiosity that enable noninvasive, *in vivo* testing of circulation,

* **Corresponding author Rafael Muci Mendoza:** Universidad Central de Venezuela, Unidad de Neurooftalmología, Hospital Vargas de Caracas, Venezuela; Email: rafalemuci@gmail.com

since a direct fundoscopy allows for easy and bedside observation of the arterioles. This can lead to extremely important data when the resulting information is applied to other arterial territories [2].

When considered individually, the fundoscopic technique gains more importance than a blood pressure check. The reason is that it provides first-hand knowledge to the trained eye about past and future events in the disease natural history, thus providing a *three dimensional look into hypertensive patients*: 1) The acute or insidious damage to the arteries in the past, since the chronic form causes progressive arteriolosclerotic changes, unlike recently diagnosed hypertension; 2) “*Here and now*”: the current situation of arteriolar and retinal damage, manifestation of the process activity, probable diastolic blood pressure readings, and, especially, which phase of the evolution process the patient is going through: incorrectly called benign hypertension vs. accelerated-malignant hypertension; 3) The possibility of differentiating “secondary” forms of hypertension and primary hypertension, and even the possibility of going deeper into the etiologic diagnosis; 4) Prognosis of the disease in untreated patients; and 5) Objective assessment of the response to different invasive and noninvasive treatments [4].

We consider the following fundoscopic changes of hypertension, which depend on diastolic blood pressure readings:

- Arteriolar signs typical of chronic hypertension. 1) Diffuse constriction that is difficult to observe if it is not in youthful vessels with normal auto regulation (pregnancy toxemia, acute diffuse glomerulonephritis). It is reversible. 2) Focal or localized constriction: apparent notches along the arterioles where caliber narrows and axial reflex is less bright. They are easily visible and constitute morphological wall changes that cannot be reversed with treatment. A significant number of them suggest left ventricular hypertrophy (Fig. 1). 3) Irreversible generalized arteriolosclerosis: This means long-standing hypertension. It manifests as exaggerated axial reflex over arterioles, copper wiring and silver wiring of arterioles, sheathing of arterioles, and arteriolo-venous crossing changes in its four grades of progressive severity: concealment, tapering, deflection with depression and compression (Figs. 1-8).



Fig. (1). Hypertensive arteriolosclerosis – time function: Arteriolar narrowing and focal narrowing.




Fig. (2). (A) Chronic hypertensive arteriolosclerosis: Copper wiring of arteriole. Abnormal arteriovenous crossing of higher grade. Notice that the end that is distal from the crossing is wider than the proximal end, which denotes compression. A thin layer of collateral vessels can be seen adjacent to the optic disc. (B) Abnormal crossing (scanning microscopy).

Central Retinal Artery Occlusion

Silvia Mendoza¹, Sandra Zambrano², Diego Fernando Mojica² and Mitzy E. Torres Soriano^{3,*}

¹ *Retina Department, Centro Oftalmológico de Valencia (CEOVAL), Valencia, Venezuela*

² *Centro Oftalmológico de Valencia (CEOVAL), Valencia, Venezuela*

³ *Centro de la Visión Gordon-Manavella, Rosario-Santa Fe, Argentina*

Central retinal artery occlusion is a vaso-occlusive ischemic disease that causes a sudden painless loss of vision usually irreversible and unilateral. Incidence is 1 to 15 cases per 10,000 it generally occurs in the elderly, and is usually accompanied by an afferent pupillary defect [1 - 3].

The most frequent causes of obstruction of blood flow are:

1. Atherosclerosis: The deposits of cholesterol and other particles form atherosclerotic plaques. They slowly thicken towards the artery lumen causing obliteration or even complete obstruction.
2. Embolism: The ophthalmic artery is the first branch of the internal carotid artery. When the artery lumen narrows by plaques containing cholesterol or other particles, some pieces can break off, blocking the flow of the ophthalmic artery, central retinal artery or one of its branches. The severity of vision loss depends on the area of obstruction.
3. Collagenosis and coagulopathy [3 - 5].

Risk factors: Hypertension, hypercholesterolemia, blood dyscrasias, vasculitis.

* **Corresponding author Mitzy E. Torres Soriano:** Centro de la Visión Gordon-Manavella, Montevideo 763, CP 2000, Rosario - Santa Fe, Argentina; Tel: +54 (0341) 4400239; E-mail: mitzytorres@yahoo.com

ESSENTIALS OF DIAGNOSIS

Symptoms

- Sudden painless loss of vision can last for seconds, minutes or be permanent.
- Usually unilateral.
- Loss of the entire visual field if the central retinal artery is affected or partial loss if a branch is affected.
- Most patients have a history of previous episodes of amaurosis fugax.

Fundus Findings

- Whitish discoloration of the retina, due to edema of the inner retinal layers, especially at the posterior pole where the nerve fiber layer and ganglion cell layer are thickest (Figs. 1-4) [1 - 6].



Fig. (1). Central retinal artery occlusion: Note pale retina, narrowed arterioles and “cherry red spot” in macula.

- Cherry-red spot. Visualization of the choroid and retinal pigment epithelium with xanthophyll pigment in the foveal area, surrounded by edematous retina (Figs. 1-4) [1 - 5].
- Retinal arterial attenuation [4].
- Optic disc edema and pallor [4].
- At later stages, fundoscopic findings include optic atrophy, retinal arterial attenuation, cilioretinal collaterals, and macular retinal pigment epithelial changes [4].

Complementary Exams

- Fluorescein angiography: to assess if the arterial obstruction is complete or partial and to determine if there is reperfusion (Figs. 2, 4).




Fig. (2). A. Fundus photograph showing retinal pallor and a cherry-red spot. B and C. Early to mid stages of the fluorescein angiogram showing significant delay in the vascular filling. There is a small area adjacent to the optic disc that is still perfused by a cilioretinal artery. D. Late Phase of the Angiogram.

Branch Retinal Artery Occlusion and Cilioretinal Artery Occlusion

Raul Velez-Montoya*

Retina Department, Asociación para Evitar la Ceguera en México, IAP. Mexico City, Mexico

Branch retinal artery occlusion (BRAO) is an arterial occlusive disease in which the obstruction of blood flow is located after the bifurcation of the central retinal artery in its major branches. The severity of the clinical manifestations will depend on the exact localization of the obstruction which can be found anywhere from the emergence of the major temporal or nasal arcades to the small capillary arterioles [1, 2].

BRAOs are thought to represent 38% of all acute retinal artery obstructions [3]. It is classified according to its visual outcome in *transient* and *permanent* BRAO [2, 4, 5]. Diabetes mellitus, arterial hypertension, ischemic heart disease, and transient ischemic attacks/cerebrovascular accidents are more prevalent in patients with BRAO than the matched US population ($p < 0.001$) [2]. Smoking prevalence in female patients with BRAO is higher; although this association has not been proven in male patients. When comparing BRAO with central retinal artery occlusion (CRAO), only diabetes mellitus has a slightly higher prevalence among patients with CRAO [2].

Embolism is the most common cause of BRAO [5, 7]. There are three main types of retinal emboli: calcific (10.5%), cholesterol (74%), and platelet-fibrin (15.5%) [6, 7]. The most common sources of emboli are the carotid artery (plaque) and the heart (valvular lesions, atrial fibrillation, patent foramen ovale, tumors in left

* **Corresponding author Raul Velez-Montoya:** Retina Department, Asociación para Evitar la Ceguera en México, Vicente García Torres, 46. San Lucas Coyoacán, México DF.04030; México; Tel: +52.55.10841400; Fax: +52.55.10841404; Email: rvelezm@yahoo.com

atrium and myxoma) [8]. Due to the fact that microemboli are responsible for most BRAO, and the major source of microemboli is an arterial plaque, the absence of an abnormal carotid doppler does not rule out the carotid artery as the source of microemboli [7, 9].

ESSENTIALS OF DIAGNOSIS

Conversely to CRAO patients, in which visual loss can be severe (light perception) at presentation, more than 70% of patients with *permanent* BRAO, seen within 7 days of onset, will have 20/40 or better at the initial visit especially if the affected vessel is the inferior temporal artery. Furthermore, 80% of patients with decreased visual acuity (VA) at presentation (worse than 20/40) will experience an improvement of VA within 1 week after onset. Final VA of 20/40 or better is seen in 89% of patients, and only 3% of eyes experience a worsening of VA during follow-up. The most frequently reported visual field defects are a central scotoma (20%) and inferior central altitudinal defect (13%), which tend to improve in 47% of the cases within 1 week of onset. In patients with *transient* BRAO, VA at presentation of 20/40 or better is seen in more than 90% of cases. The central and peripheral visual field remains normal. Final VA tends to be 20/40 or better in virtually all cases, regardless of VA at onset (even if it was worse than 20/40) [1, 5].

During the acute phase of the disease, an area of retinal pallor corresponding to the area of compromised blood flow and oncotic damage (swelling) can be identified on fundus examination (Figs. 1, 2) [10 - 12]. However, the initial pallor is replaced by the normal sheen of the fundus in long-standing cases, making it more difficult to diagnose [10]. If there is enough ischemia, cotton-wool spots will develop 6 to 18 hours after onset, especially if the affected vessel is large enough and close to the posterior pole where the nerve fiber layer is thicker [13, 14]. A retinal emboli is seen in 47% of cases. However, its absence does not rule out an embolic case because it may have disintegrated, migrated and disappeared by the time the eye is examined [15, 16].




Fig. (1). BRAO on a diabetic patient after pars plana vitrectomy and silicon oil. **A)** Color photograph shows whitening of the posterior pole with normal color of the papillomacular bundle. **B)** Red-free photograph shows more clearly the territory supplied by the cilioretinal artery on the same patient.




Fig. (2). Acute phase of inferotemporal BRAO. **A)** Fundus photograph shows retinal pallor in inferior macular area. **B** and **C)** FA shows a delay on the vessel filling and transit time. **D)** Cattle trucking and staining of the vessels walls (Courtesy of Natalia Pecce MD, Argentina).

Retinal Arterial Macroaneurysm

Rodrigo Lechuga Perezanta¹ and Virgilio Morales Cantón^{2,*}

¹ *Asociación para Evitar la Ceguera en Mexico, Mexico City, Mexico*

² *Retina Department, Asociación para Evitar la Ceguera en Mexico, Mexico City, Mexico*

The term macroaneurysm was first coined by Robertson, in 1973 making reference to arterial retinal lesions with saccular or fusiform swelling, localized on the first three orders of the retinal arterial tree found mainly at arterial bifurcations [1]. Saccular arterial macroaneurysms are more likely to burst and develop closer to the optic nerve where perfusion pressure is higher. Retinal arterial macroaneurysms are more frequent in women (60 – 80% probably due to hormonal and hereditary factors) with an average age of 69 years and have a strong association with systemic diseases such as arterial hypertension, atherosclerotic disease, hyperlipidemia, polycythemia and cerebrovascular disease. Retinal arterial macroaneurysms have been described in Leber's miliary aneurysms, Coats' disease, branch retinal artery occlusion and Eales' disease among others [1, 2].

Systemic arterial hypertension causes an increase in hydrostatic pressure and may lead to hyaline degeneration of the vascular wall, loss of autoregulation tone and arterial dilatation [2].

Another theory to support that systemic arterial hypertension is a risk factor to the formation of arterial macroaneurysms is Laplace equation, which states that an increase in the transmural pressure is directly proportional to the increased tension of the wall.

Focal embolic damage to the arterial wall is considered to be a part of the

* **Corresponding author Virgilio Morales Cantón:** Retina Department, Asociación para Evitar la Ceguera en Mexico, Vicente García Torres 46, San Lucas Coyoacan, Mexico City, 04030; Mexico; Tel +52 (55) 10841400, Email: vmoralesc@mac.com

mechanism for lesion formation, which may result in localized ischemia.

ESSENTIALS OF DIAGNOSIS

Most of these lesions appear on the superotemporal arterial branch (51%), followed by the inferotemporal branch (28%). Macroaneurysms affecting the nasal arterial branches may be less frequently diagnosed because patients may not notice the loss of visual acuity until the macula is affected, which could not happen, or a vitreous hemorrhage develops. Usually one macroaneurysm is present, but more lesions have been described affecting the same eye and 10% may be bilateral.

The main symptom is decreased visual acuity as a consequence of exudation, edema or hemorrhage. A characteristic finding is the presence of hemorrhage in different layers including subretinal, intraretinal, sub internal limiting membrane (Figs. **1A**, **2A** and **3A**) or in the vitreous cavity [1, 3]. Hourglass hemorrhages are also a typical finding.

These lesions may develop symptoms when acute or chronic decompensation occurs. Acute decompensation is typically associated with rupture and hemorrhage of the macroaneurysm while chronic decompensation is due to abnormal leakage of plasma constituents across the aneurysmal wall leading to the accumulation of yellow perianeurysmal intraretinal exudates [4].

When the arterial macroaneurysm is visible during fundus examination, the correct diagnosis can be achieved without much trouble, but when massive hemorrhage, exudation or retinal edema are present they suppose a diagnostic challenge. Fluorescein angiography (Figs. **1B**, **2B** and **3B**) is useful to locate the lesion when dense hemorrhage is absent so hyperfluorescence is visible. Macroaneurysm typically shows hyperfluorescence during the early arterial phase of the angiogram but late phase varies from little staining of the vessel wall to marked leakage. The absorption and emission spectrum of indocyanine green are close to infrared range and this allows the dye to be seen through hemorrhage. This makes indocyanine green a good alternative when diagnostic dilemma is present due to dense hemorrhage or exudates [5, 6].




Fig. (1). A 74-year-old female patient complains of floaters and photopsia in her left eye from 8 days ago. Diagnosis of systemic arterial hypertension was made 20 years before. Visual acuity was 20/100, intraocular pressure 16 mmHg, fundus examination revealed subretinal and intraretinal hemorrhage (A) and fluorescein angiography showed a hyperfluorescent lesion in the superior temporal arterial vessel in the second branch (B). No treatment was performed and visual acuity was recovered to 20/60 three months later.

Macular Telangiectasia

Yogin Patel¹ and Michael D. Ober^{1,2,*}

¹ Department of Ophthalmology, Henry Ford Health System, Detroit, MI, USA

² Retina Consultants of Michigan, Southfield, MI, USA

Macular telangiectasia (MacTel) was best classified and described by Gass and Blodi as a form of idiopathic juxtafoveolar retinal telangiectasis [1] and is also commonly referred to as idiopathic perifoveal telangiectasia. This is a group of disorders which affects the vasculature of the posterior pole. Numerous classification schemes have been designed to categorize it, most notably, that of Gass and Blodi [1] and an update by Yannuzzi *et al.* [2]. Two major subclassifications are of greatest importance; MacTel type 1 refers to a unilateral presentation with prominent microaneurysms that is often grouped within the spectrum of Coats disease. MacTel type 2 is more often referred to simply as MacTel, and represents an acquired bilateral retinal vascular disorder. For the purposes of this review, we will focus on MacTel type 2.

Different studies quote very different numbers for the prevalence of this condition ranging from as high as 0.1% in the Beaver Dam Eye Study to 0.0045 to 0.022% in the Melbourne collaborative cohort study [3, 4]. The age at onset is usually in the late 40s to early 60s. There may be a slight female predominance depending on the study population quoted.

ESSENTIALS OF DIAGNOSIS

Patients will often present with a pericentral scotoma or metamorphopsia. Visual acuity rarely progresses to legal blindness but visual dysfunction is common. The clinical presentation begins with subtle changes noted in the posterior pole.

* Corresponding author Michael D. Ober: Retina Consultants of Michigan, 29201 Telegraph Road, Suite 606, Southfield, MI 48034, USA; Tel: (248) 356-8610; Fax: (248) 356-6473; E-mail: obermike@gmail.com

Lesions most often begin just temporal to the fovea (Figs. 1A, B). They may then further evolve to include the larger perifoveal region. The initial presenting change is often a loss of transparency in the retina temporal to the fovea. With time the lesion may evolve to include dilation of capillaries and will likewise spread from their temporal perifoveal origin. Histological studies have demonstrated that the dilated capillaries are mostly located in the deeper retinal layers [1]. Although, Yannuzzi and others have observed the involvement of both the superficial and deep plexus [2]. Later changes include dilated venules, which are often associated with the abnormal capillaries. These vessels tend to increase in diameter as they approach the fovea, in contrast to normal vessels. In addition, these vessels often take characteristic right angle turns, which represent diving of the vessel toward the deeper retinal layers. Associated changes in the RPE include crystalline deposits (Figs. 3A, B), pigment migration, and hyperplasia following these venules [2]. Over the time, secondary atrophy of the pigment epithelium and neurosensory retina may develop. Some eyes may accumulate vitelliform material under the central macula. Lamellar thinning of the inner retina within the fovea is common and manifests with the development of inner lamellar cystic changes (Fig. 4). On occasion the atrophic changes may progress to a full thickness macular hole.

Neovascularization is another common later stage development usually preceded by the appearance of the right angle venules and pigmentary changes. As with any neovascularization, it may be associated with hard exudate, edema, and hemorrhage. The neovascularization stems from retinal vessels, but may be indistinguishable from choroidal neovascularization with chorioretinal anastomosis from other etiologies. Late changes may include the formation of a disciform scar.

Multimodal imaging is critical in the diagnosis of MacTel. One of the earliest signs of the disease, even before clinical changes appear, is the loss of the hypofluorescent center in fundus autofluorescence photos which later progress to more pronounced hypoautofluorescence corresponding to RPE atrophy with adjacent granular hyperautofluorescence (Figs. 5A, B). This has been postulated as a direct result of the depletion in macular pigment [5]. Fluorescein angiography (FA) findings are often diagnostic and include the characteristic telangiectatic




Fig. (1). (A and B) Color fundus photographs demonstrating the subtle loss of retinal transparency and right angle vessels most notable temporal to both foveae. Retinal pigment epithelial hyperplasia can be seen surrounding the right angle vessels (not shown here). Vessels temporal to the fovea are noted to be of irregular caliber and telangiectatic (Photo Credit: Colin Griffin).

Sickle Cell Retinopathy

Luke B. Lindsell and Aziz A. Khanifar*

Retina Group of Washington, Washington DC, USA

ESSENTIALS OF DIAGNOSIS

Sickle cell disease is an autosomal recessive condition comprising several different forms of mutated hemoglobin. Patients who are homozygous for the hemoglobin S gene (HbS) have the most severe form of sickle cell anemia. Other genotypes of clinical importance to ophthalmologists include HbSC disease (double heterozygote for HbS and HbC), HbS/b-thal (double heterozygote for HbS and beta-thalassemia), and sickle cell trait (one normal Hb allele and one HbS allele). In general, patients with the more severe genotype of sickle cell disease have less severe ophthalmic manifestations. For example, HbSS has the most critical systemic complications, the ocular manifestations are less severe compared to HbSC disease which has a more moderate systemic course. Although sickle cell trait is relatively asymptomatic, under hypoxic conditions both systemic and ophthalmic consequences can occur [1].

Relative hypoxia causes mutated hemoglobin to polymerize, ultimately altering the morphology of the red blood cell (RBC) to the characteristic sickle shape. These abnormal RBCs occlude terminal arterioles, leading to ischemia and possible tissue infarction [2]. Sickle cell retinopathy is one end-organ manifestation of the disease. Similar to diabetic eye disease, both non-proliferative and proliferative forms occur, and the proliferative disease is associated with more significant visual morbidity [3].

* **Corresponding author Aziz A. Khanifar:** Retina Group of Washington, Washington DC, USA; Tel: (301) 495-2357, Fax: (301) 495-2359; E-mail: azizkhanifar@gmail.com

Non-proliferative sickle cell retinopathy is characterized by several possible findings:

1. Vascular tortuosity – more common in HbSS disease (Fig. 1).
2. Salmon patch hemorrhages – located between the internal limiting membrane (ILM) and retinal surface (“blowout” of occluded arteriole) [4] (Fig. 2).
3. Intraretinal hemorrhages (Fig. 1).
4. Iridescent spots – small schisis cavity in area of resolved intraretinal hemorrhage. Hemosiderin-laden macrophages appear as glistening spots [4] (Fig. 3).
5. Black sunburst – flat areas of hyperpigmentation resulting from intraretinal hemorrhage infiltrating the subretinal space and damaging the retinal pigment epithelium (RPE) (Fig. 4).



Fig. (1). Color photo montage. Resolving intraretinal hemorrhage that will become a sunburst or possibly iridescent spots (black arrow). Faint resolving salmon patch hemorrhage (yellow arrow). Vitreous hemorrhage (white arrow). Vascular tortuosity is also evident.




Fig. (2). Color photo. Large peripheral salmon patch.



Fig. (3). Color photo. Iridescent spots.

Radiation Retinopathy

Veronica Kon Graversen*

University of North Carolina at Chapel Hill, NC, USA

Radiation retinopathy (RR) is the result of ultra-structural impairment of the vascular endothelial cells and pericytes of the retina and choroid after exposure to ionizing radiation [1]. Several factors influence the development of retinopathy, including the type of radiation received (external-beam irradiation *versus* local radioactive plaque therapy), total dosage and fraction size schemes used, concomitant systemic vascular diseases, simultaneous chemotherapy, and pregnancy [2, 3]. These factors determine the interval to onset and severity of the disease. The dose required to produce retinopathy is variable, but it is generally accepted that exposure to 30-35 Gray leads to visual changes [3]. The median time interval to onset of retinopathy is 27 months but may range from few months to several years [4].

ESSENTIALS OF DIAGNOSIS

Photoreceptors are relatively preserved and resistant to the radiation effects. Therefore, the degree of visual loss depends on the severity of the occlusive vasculopathy and its sequelae.

Clinical Features: The earliest signs include capillary dilation and microaneurysm formation. Later in the course of the disease, a nonproliferative phase may develop. This phase is exudative. Hard exudates, intraretinal (superficial or deeper) and preretinal hemorrhages, telangiectasia, cotton wool spots and macular edema are frequently seen (Figs. 1 and 2).

* Corresponding author **Veronica Kon Graversen**: Ophthalmology Department, University of North Carolina at Chapel Hill, NC, USA; Tel: (919)518-6361; Email: veronicakonjara@gmail.com



Fig. (1). Fundus photograph of a patient treated with ophthalmic plaque radiation for choroidal melanoma. The patient developed non-proliferative radiation retinopathy, showing retinal hemorrhages, hard exudates and telangiectasia.

Extensive retinal ischemia may lead to vascular occlusions, retinal neovascularization (Fig. 2), vitreous hemorrhage, retinal detachment, and, in some cases, neovascular glaucoma. These late changes are recognized as the proliferative phase of the disease [1, 3].

Rarely, choroidal neovascular membranes (CNV), chorioretinal anastomosis and intravitreal polypoidal neovascularization have been reported [5 - 7].

Imaging. The diagnosis is mainly clinical; however, retinal diagnostic imaging provides valuable tools monitoring the progression of the disease and treatment response.

Optical coherence tomography: Ensures early recognition of macular changes. More severe and chronic cases may reveal outer retinal disruption [8].

Fluorescein angiography: Initial findings include varying degrees of capillary closure and dilation of microvasculature (Fig. 2). The most affected areas are the peripapillary region and the macula [9].

Indocyanine green angiography: Detects areas of choriocapillaris perfusion defects [10].



Fig. (2). Fundus photograph shows microaneurysms, hard exudates and and retinal hemorrhages. Fluorescein angiography reveals microaneurysms, capillary closure and retinal neovascularization.

DIFFERENTIAL DIAGNOSIS

1. Diabetic retinopathy.
2. Retinal vascular occlusions.
3. Occlusive retinopathy.
4. Retinal telangiectasia.
5. Human immunodeficiency virus retinopathy.
6. Hypertensive retinopathy.

MANAGEMENT

There are no specific treatment guidelines for radiation retinopathy. Macular ischemia is usually irreversible and is the most feared complication that results in blindness. Focal laser treatment can be applied to areas of macular edema [11]. In recent years, intravitreal or periocular steroids and anti-vascular endothelial growth factor (VEGF) therapies have been successfully used to treat center-involving macular edema [11 - 13]. Bevacizumab has been the most studied anti-VEGF in cases of radiation retinopathy. Nevertheless, similar outcomes have been reported with other anti-VEGF agents. Refractory cases may benefit from

Ocular Ischemic Syndrome

Eleonora Lavaque*

Retina Department, Hospital Oftalmológico Santa Lucia, Buenos Aires, Argentina

Retina Department, Instituto Médico de Ojos, Buenos Aires, Argentina

Ocular ischemic syndrome (OIS) is caused by ocular hypoperfusion. Carotid stenosis superior to 70% or complete occlusion due to atherosclerosis is the common cause of this rare condition. In 80% of the cases, OIS is found unilaterally, on the same side of the carotid stenosis [1, 2]. Occasional causes of OIS secondary to ophthalmic artery obstruction include Takayasu disease or giant cell arteritis [3].

Described risk factors are: age between 50-80 years, male gender 2:1, and vascular diseases such as arterial hypertension (75%), diabetes (56%), coronary diseases, vascular stroke and hemodialysis [3 - 5].

ESSENTIALS OF DIAGNOSIS

Ninety percent of the patients present with a history of slowly progressive visual loss in the affected eye. Dull ischemic pain develops gradually and is relieved when the patient lies down [4, 5].

Anterior segment ischemic signs include iris or angle neovascularization, iridocyclitis with flare and cells in 20% of cases, cataract, iris atrophy, sluggish pupillary reaction to light [1]. Other less common signs of OIS are dilatation of conjunctival and episcleral vessels, corneal edema, and bullous keratopathy [4, 6].

Posterior segment signs are more frequent than anterior segment signs [4]. Posterior segment ischemic signs include narrow retinal arteries, perifoveal telangi-

* **Corresponding author Eleonora Lavaque:** Retina Department, Hospital Oftalmológico Santa Lucia, Buenos Aires, Argentina; Tel: 00-9-54-56458302; Fax: 00-54-11-48124494; E-mail: eblavaque@hotmail.com

ectasia, dilated retinal veins, mid-peripheral retinal hemorrhages and microaneurysms. Neovascularization in the optic disc or retina and its complications (fibrovascular proliferation, cotton-wool spots, vitreous hemorrhage) may be present but are not frequent (Figs. 1-3) [3, 4].




Fig. (1). Fundus photograph shows round circumscribed hemorrhages at the classical midperipheral location.



Fig. (2). 70-year-old Caucasian male patient. Medical background: diabetes, hypertension, coronary bypass, acute ischemic cerebral stroke, recent left carotid surgery, endarterectomy 2 months before, and indication for future right carotid endarterectomy because of 79% stenosis. Best-corrected visual acuity was 20/40 in the right eye, and hand motion in the left eye. Positive biomicroscopy: rubeosis iridis, hyphema in left eye. Intraocular pressure 15/60 mm hg. Fundus photograph of the right eye: preretinal hyaloid fibrosis, preretinal hemorrhage at an arteriovenous crossing. Ocular fundus findings in left eye: vitreous hemorrhage.




Fig. (3). Left eye of the same patient as Fig. (2), after vitrectomy and endophotocoagulation. Round hemorrhages and photocoagulation scars are present. After vitrectomy, visual acuity improved to 20/100, intraocular pressure improved to 26 mmHg with topical treatment.

A cherry-red spot, characteristic of macular ischemia, is seen in 12% of eyes, due to IOP exceeding the perfusion pressure or to a result of embolic occlusion of the central retinal artery [1, 4].

Eighty percent (80%) of OIS present with very characteristic retinal hemorrhages: they are round, located in the external retinal layers, and at the mid-periphery (Fig. 1) [2, 3].

Intraocular pressure is usually normal or low. Although anterior segment neovascularization is frequent, elevated intraocular pressure is less common than expected due to flow restriction to the ciliary body. Normal-tension glaucoma can be present in eyes with normal ocular tension due to hypoperfusion to the optic disc [1, 2, 4].

In fluorescein angiography, 60% presents prolonged arm-to-choroid and arm-to-retina circulation time (Fig. 4). The normal retinal filling time is approximately 5 seconds, but in the affected eye it may be 1 minute or longer [4].

Dry Age-Related Macular Degeneration

Ana Domínguez Yates and Virgil Alfaro*

Retina Consultants of Charleston, Charleston, South Carolina, USA

Age related macular degeneration (AMD) is a progressive and chronic disorder, characterized by the onset of degenerative changes in the macular area in people of 50 years of age or older [1]. Besides age, other risk factors are white race [2], smoking [3, 4] and female gender [5, 6]. Advanced AMD, is the leading cause of severe central vision loss in this age group, and geographic atrophy (GA) is responsible for 25% of cases. The Pathophysiologic mechanism still remains unclear but it is well known that the Retinal Pigment Epithelium (RPE) plays a key role [7]. Environmental and genetics factors can alter any given patient's susceptibility to the disease [8].

ESSENTIALS OF DIAGNOSIS

The changes in AMD involve the outer retina, RPE, Bruch's membrane and choriocapillaris [9]. Drusen are the hallmark features of AMD. They become visible on biomicroscopic fundus examination when their diameter exceeds 25 μm . They can be classified [10] by size as small (< 0-63 μm diameter), medium (64-124 μm diameter) or large (> 0-125 μm diameter) (Fig. 1).

According to their appearance they can be classified as hard or soft. Hard or crystalline drusen (Fig. 2) appear as small, round yellow-white spots with sharp borders. They correspond to accumulation or entrapment of hyaline material, lipids and mucopolysaccharides underneath RPE [11, 12]. Large areas of small hard drusen increase the risk of soft drusen and RPE atrophy at a relatively young age [13, 14]. Soft drusen are pale yellow-white spots, more than 63 μm in diame-

* **Corresponding author Virgil Alfaro:** Retina Consultants of Charleston, 3531 Mary Ader Ave # D, Charleston, SC 29414, Estados Unidos, USA; Tel: +1 843-763-4466; E-mail: virgil.alfaro@gmail.com




Fig. (1). 60-year-old patient with Dry AMD and visual acuity of 20/20 in both eyes. Small drusen (filled arrow); medium drusen, with a diameter equal or greater than one half of a large drusen (arrowhead); and large drusen, diameter greater than or equal to a large vein at the disc margin (unfilled arrow).



Fig. (2). Some small drusen in the superior macula in a 61-year-old patient. Hard drusen appear bright with sharp and very well defined borders (unfilled arrow).




Fig. (3). Soft drusen in a 77-year-old patient. Big and pale yellow–white lesions ill-defined margins (arrow).

ter, with ill-defined boundaries, are preferentially located within the fovea (Fig. 3). They are a result of RPE dysfunction and derive from basal linear deposits, between the RPE and the Bruch's membrane [11, 12]. Most of the molecular constituents of drusen reflect their complex pathogenesis: protein (immune response modulator; immunoglobulin and complement components; inflammation molecules), cellular components (RPE blebs, lipofuscin, and melanin, as well as choroidal dendritic cell), glycoconjugates, neutral lipids and zinc [15].

On Fluorescein angiography (FA), hard drusen appear as a bright early hyperfluorescence secondary to window defects (Fig. 4 a-c). On the other hand, soft drusen appear as progressively hyperfluorescent spots that persist in late phases due to staining (Figs. 5 a-d and 6 a-c).

Wet Age-Related Macular Degeneration

Gerardo García-Aguirre^{*,1,2}

¹ Retina Department, Asociación para Evitar la Ceguera en Mexico, Mexico City, Mexico

² Ophthalmology, Escuela de Medicina - Tec de Monterrey, Mexico City, Mexico

Age-related macular degeneration (AMD) is one of the leading causes of legal blindness in patients over 60 years, especially in developed countries [1]. The prevalence of the disease varies according to ethnicity [2], and is more common in smokers [3, 4] and in women [5, 6]. The disease is classified in two stages, known as dry AMD (which is discussed in another chapter) which is characterized by the presence of drusen in the posterior pole, and wet AMD, in which the patient develops neovascularization that stems from the choroid, penetrates Bruch's membrane, and by leakage of fluid, hemorrhage and scarring, affecting the center of the macula.

ESSENTIALS OF DIAGNOSIS

When a choroidal neovascularization (CNV) develops, patients may complain of metamorphopsia and a central or paracentral relative scotoma.

Clinical examination usually reveals drusen, and the presence of intraretinal or subretinal fluid that causes thickening of the retina. Hemorrhage and hard exudates may also be observed (Figs. 1-6).

* Corresponding author Gerardo García Aguirre: Retina Department, Asociación para Evitar la Ceguera en Mexico, Vicente García Torres 46, San Lucas Coyoacan, Mexico City 04030, Mexico; Tel: +52 (55) 10841400; E-mail: jerry_gar_md@yahoo.com



Fig. (1). Fundus photograph of the right eye with subfoveal CNV showing multiple soft and hard drusen in the macular area. A small subretinal hemorrhage may be observed nasal to the fovea.




Fig. (2). Fundus photograph of the right eye with a subfoveal CNV and large submacular hemorrhage.




Fig. (3). Red-free fundus photograph of the left eye, showing a subfoveal CNV surrounded by hard exudates and submacular hemorrhage.



Fig. (4). Fundus photograph of the left eye displaying an extrafoveal CNV, just adjacent to the inferotemporal border of the optic nerve, with associated subretinal hemorrhage.

Polypoidal Choroidal Vasculopathy

Jans Fromow Guerra*

Retina Department, Asociación para Evitar la Ceguera en México, IAP, México City, México

ESSENTIALS OF DIAGNOSIS

Polypoidal choroidal vasculopathy (PCV) is a retinal disorder involving the choroidal vasculature characterized by the presence of aneurysmal polypoidal dilations that commonly arise from a network of branching choroidal vessels, that was described in 1982 by Lawrence Yanuzzi. PCV usually shows a broad spectrum of manifestations both clinically and epidemiologically. For this reason, it has been widely debated whether to consider it a subtype of neovascular age-related macular degeneration (AMD) or a separate clinical entity. Some of the characteristics of PCV are shared by AMD but some others are radically different.

Epidemiology Essentials of PCV

- PCV predominantly occurs at a mean age of 68.4 years with a range of 21-93 years [1 - 3].
- PCV is more prevalent in non-Caucasians, such as Asians and African-Americans where it has been reported to be responsible up to 23-54.7% of wet AMD cases in these populations [4]. However, in Caucasians the prevalence of this disease has been reported in about 8-13% [5].
- PCV is more prevalent in females than in males in Caucasian (female 52% to 65%) populations and the opposite in Asians (men 63% to 78%) [2].

* **Corresponding author Jans Fromow Guerra:** Retina Department, Asociación para Evitar la Ceguera en México, IAP, Vicente García Torres, 46. San Lucas Coyoacán, México DF. México 04030; Tel: +52.55.10841400; Fax: +52.55.10841404; E-mail: fromow@me.com

Clinical Essentials of PCV

- Localization: PCV can present in different regions: peripapillary, macular or extramacular. Prevalence of each one of these presentations varies according to different ethnic groups [6]. Different reports state that unilateral disease can be found in up to 79.4% to 91.8% of cases [6 - 8].
- Clinical appearance: Clinical examination will reveal orange-reddish colored vascular dilatations often associated to pigment epithelial detachments (PED), subretinal hemorrhage, hard exudates and drusen (Fig. 1).



Fig. (1). Clinical appearance of peripapillary PCV.

- Angiographic & OCT Analysis (Figs. 2-6): Indocyanine green angiography (ICGA) should be considered as the gold standard in PCV diagnosis since findings in FA can be easily mistaken for wet AMD especially in elderly patients with drusen and bilateral disease [8, 9]. ICGA will often reveal single or multiple polyps appearing as vascular aneurysmal dilatations arising from inner choroidal vessels often seen as a neovascular plaque or a so-called “branching vascular networks” (BVN). These findings are usually seen within the first 6 minutes after the injection of ICG [10]. However, PCV lesions may not be easily seen due to minor or extensive hemorrhage. A classification of PCV has been developed regarding the presence or absence of BVN determined by ICGA:

Type I PCV or “Polypoidal CNV” with an apparent BVN and type 2 PCV or “Typical PCV” with no or faint BVN. These 2 different PCV subtypes have distinct clinical course, treatment response and genetic background [11 - 13]. OCT shows important diagnostic characteristics (Figs. 2, 3 and 6). In most cases a sharp elevated PED is observed, that may be associated to a flat, shallower PED. Polypoidal lesions are usually attached to the back surface of the elevated PED. In type I PCV the flat shallower PED is associated with the BVN giving a “double layer sign” [14].




Fig. (2). ICGA and OCT appearance of peripapillary PCV of the same patient as Fig. (1).




Fig. (3). Left: ICG-Macular Type 2 PCV with no or faint branching vascular network. Right. OCT image where an associated PED can be clearly observed.

Retinal Angiomatous Proliferation (RAP)

Maximiliano Gordon^{1,2,*} and Guillermo Gordon[†]

¹ *Centro de la Visión Gordon-Manavella, Rosario, Santa Fe, Argentina*

² *Retina Department, Ophthalmology Service, Hospital Provincial del Centenario, Rosario, Santa Fe, Argentina*

Retinal Angiomatous Proliferation (RAP), or type 3 neovascularization, is a different form of exudative age-related macular degeneration (AMD) [1]. Its main characteristic is an abnormal anastomosis between the choroidal and the retinal vessels. The pathogenesis of this entity remains controversial [2 - 4]. Yannuzzi *et al.* believe that the neovascular process originates within the neurosensory retina. In contrast, Gass proposed that the process begins with choroidal neovascularization (CNV) [1].

Gass' classification scheme is based on neovascularization relationship to the retinal pigment epithelium (RPE). Type 1 neovascularization describes new blood vessels growing under the RPE, while in Type 2 neovascularization these proliferate over the RPE. Freund has proposed modifying Gass' original classification by adding Type 3 neovascularization, which refers to a type of neovascularization with preference for the retina [1].

ESSENTIALS OF DIAGNOSIS

Symptoms are similar to those of AMD. However, patients with RAP tend to be older. The classical findings include retinal and preretinal hemorrhages, and pigment epithelial detachments, as well as small and multiple intraretinal blood [5].

* **Corresponding author Maximiliano Gordon:** Centro de la Visión Gordon - Manavella, Montevideo 763, CP 2000, Rosario - Santa Fe, Argentina; Tel/Fax: +54(341)4400239/4244850; E-mail: maximilianogordon19@gmail.com

[†] Died

RAP classification distinguishes three vasogenic stages based on the nature and progression of the neovascularization process. Stage I involves capillary proliferation within the retina originating from the deep retinal plexus (intraretinal neovascularization [IRN]). Stage II is determined by IRN extending into the subretinal space (subretinal neovascularization [SRN]). Stage III describes progression to CNV, that can be clearly determined clinically or angiographically. This stage is sometimes characterized by a vascularized pigment epithelial detachment and retinal choroidal anastomosis (RCA) [6]. Stage-I RAP lesions manifest with intraretinal neovascularization with telangiectatic retinal capillaries and small angiomatic structures perfused by the retinal circulation. Stage-II RAP lesions extend beyond the photoreceptor layer into the subretinal space resulting in subretinal neovascularization. A serous PED is often seen. In stage-III RAP, it is presumed that an RCA is formed. Patients that are not treated for stage-III RAP lesions can develop large fibrotic scars [7]. In these cases, fluorescein angiography revealed poorly defined staining that simulates occult CNV (Figs. 1 and 3).

Indocyanine green angiography (Fig. 3) often helps make an accurate diagnosis. It revealed a focal area of hyperfluorescence corresponding to the neovascularization (“hot spot”). OCT may reveal intraretinal hyperreflectivity, corresponding to angiomatic proliferation associated with intraretinal or subretinal fluid (Figs. 2 and 4) and/or RPE detachment [6]. Dilated fundus exam showed hemorrhages and lipid exudates in an area of occult CNV on the basis of fluorescein angiography and indocyanine green angiography (ICG) revealed the presence of a hot spot. These findings led to the diagnosis of RAP [6, 7].

DIFFERENTIAL DIAGNOSIS

Differential diagnosis should include other forms of CNV with ICG hot spots (occult CNV) and polypoidal choroidal vasculopathy (PCV). This latter disease presents with normally larger retinal hemorrhages and round reddish-orange macular lesions in the eye fundus. OCT is also a helpful tool in differentiating RAP, PCV, and occult membranes. In PCV, polyps appear in OCT as abrupt neurosensory detachment. Other differential diagnosis is macular telangiectasia.




Fig. (1). A 73-year-old woman with retinal angiomatous proliferation. Fundus photograph and autofluorescence revealing perifoveal lesion (**a** and **b**). Fluorescein angiogram showing hyperfluorescence with diffuse leakage of dye (**c-f**) (Courtesy of Alejandro Lavaque, Argentina).




Fig. (2). OCT of the same patient shown in Fig. (1). OCT scans showing subretinal fluid and hyperreflective subretinal lesion (Courtesy of Alejandro Lavaque, Argentina).

Choroidal Neovascular Membrane in Degenerative Myopia

Federico Furno Sola^{1,2,*}

¹ *Ophthalmology Service, Sanatorio Mapaci, Rosario, Santa Fe, Argentina*

² *Grupo Laser Visión, Rosario, Santa Fe, Argentina*

ESSENTIALS OF DIAGNOSIS

Myopia is a common condition in many countries, particularly in East Asia, affecting approximately 40% of Chinese adults older than 40 years. The prevalence of myopia in developed countries is reported to be between 11% and 36%. The overall prevalence of pathologic myopia is approximately 1% to 4% in the general adult population although there is a wide geographical variation. The associated prevalence of visual impairment due to pathologic myopia is estimated to be 0.1% to 1.4%. The definition of pathologic myopia is not standardized, but is historically classified in clinical trial literature as a myopic refractive error greater than -6 diopters, or an axial length >26 mm, associated to degenerative changes involving the sclera, choroid and retina. Choroidal neovascularization secondary to pathological myopia is a common vision-threatening complication and often affects adults of working age, and develops in approximately 5% to 10% of patients with pathological myopia. The overall prevalence of choroidal neovascularization secondary to pathological myopia is therefore estimated to be approximately 0.04% to 0.05% in the general population [1, 2].

The chorioretinal lesions are viewed as a consequence of excessive axial elongation. It is believed that progressive distension of the posterior pole stretches the retina, choroid and sclera, as evidenced by the straightening of the temporal

* **Corresponding author Federico Furno Sola:** Grupo Laser Visión, Mariano Moreno 1397, Rosario – Santa Fe, Argentina; Tel: +54 (0341) 4472122; Email: furnosola@gmail.com

retinal vessels, the appearance of peripapillary atrophy, and the thinning of the retina and choroid. Various changes may occur in the fundus of a patient with myopia, related to the presence of myopic conus, staphylomas, retinal pigment epithelium and choroid disturbances and atrophic areas (Figs. 1-3). Lacquer cracks are linear or stellate; the lines are fine, irregular in caliber, yellowish-white, horizontally oriented, single and/or multiple. Lacquer cracks are ruptures of Bruch's elastic lamina and carry a guarded visual prognosis because of their association with focal degenerative lesions and subretinal neovascularization along their course [1, 2].

It is generally accepted that the pigmented lesion described by Fuchs and the hemorrhagic lesion reported by Foerster represent different stages of the process of the development of CNV in myopia (Fig. 2). Neovascularization has been identified to precede the development of Fuchs spots. The growth of choroidal new vessels induces a sudden painless reduction in vision usually associated with metamorphopsia. Biomicroscopically, it is observed as a light-gray, round or elliptic macular lesion (Fig. 3). The lesion is usually discrete in size and located next to the fovea [1, 2].



Fig. (1). Numerous areas of pigment epithelium atrophy and choriocapillaris extend to the macular region. A circular myopic crescent is visible.




Fig. (2). Numerous areas of pigment epithelium and choriocapillaris atrophy extend into the macular region. A circular myopic crescent is visible. Hemorrhage occupies the center of the fovea.



Fig. (3). Numerous areas of atrophy of the pigment epithelium and choriocapillaris extend to the macular region. A circular myopic crescent is visible. Choroidal new vessels with neovascular lesion and macular edema.

Angioid Streaks

Michael Larsen^{1,*}, Mette K.G. Andersen¹, Naresh Mandava² and Richard Hwang³

¹ *Department of Ophthalmology, Glostrup Hospital and Faculty of Health Sciences, University of Copenhagen, Kobenhavn Denmark*

² *Department of Ophthalmology, University of Colorado School of Medicine, Aurora, CO, USA*

³ *Vitreoretinal Disease and Surgery, Department of Ophthalmology, University of Colorado School of Medicine, Aurora, CO, USA*

Angioid streaks is the term used for a characteristic type of posterior segment lesion consisting of irregular and sometimes branching lines with a red or brownish appearance that extend from the rim of the optic disc to the periphery of the fundus (Figs. 1-4, 8A, B, 9A, B) [1]. They were originally described by Doyne in 1889 [2]. The streaks are caused by breaks in the Bruch's membrane – retinal pigment epithelium (RPE) complex [1].

Angioid streaks can be seen in the presence of various extraocular conditions, most commonly pseudoxanthoma elasticum, a connective tissue disorder caused by defects in the *ABCC6* gene [3]. It gives rise to lax and dimpled skin, mainly on the flexor side of the neck, elbows and knees (Fig. 6). The inheritance is mostly autosomal recessive, but autosomal dominant patterns can also be seen. The precise physiological function of *ABCC6* is unknown, but it can be seen to be involved in transporting intracellular elements to the extracellular space. Defects in the *ABCC6* protein lead to the accumulation of mineralized and fragmented

* **Corresponding author Michael Larsen:** Department of Ophthalmology, Glostrup Hospital and Faculty of Health Sciences, University of Copenhagen, Kobenhavn, Denmark; Email: MICLAR01@regionh.dk



Fig. (1). Angioid streaks (black arrows) of the classic red type that resemble large choroidal blood vessels. The streaks are found behind the retinal blood vessels at the level of the retinal pigment epithelium. Red streaks stain early and prominently on fluorescein angiograms. Subfoveal choroidal neovascularization is also seen in this case (white arrow).



Fig. (2). Brownish and greyish pigmented angioid streaks temporal and superior of the optic disc in a patient with pseudoxanthoma elasticum. Note also subfoveal hemorrhage and choroidal neovascularization.




Fig. (3). Parafoveal classic subretinal neovascularization of choroidal origin (black arrows) in a patient with angioid streaks, one of which can be seen superior to the optic nerve head. Fluorescein angiography (lower right) shows prominent leakage, which explains the serous detachment of the neurosensory retina (black arrowheads). The upper right part of the color fundus photograph shows the spotted orange peel (peau d'orange) appearance of the diffuse outer retinal degeneration.




Fig. (4). Angioid streaks, a mixture of brownish streaks, pale atrophic areas, mainly around the margin of the optic disc, curved streaks concentric with the disc that are reminiscent of traumatic choroidal rupture lines and a small active choroidal neovascularization of approximately 250 μm diameter at the inferonasal margin of the fovea, emanating from the inferior tip of the large pale defect of the retinal pigment epithelium.

Presumed Ocular Histoplasmosis Syndrome

Manuel Garza-León^{1,*}, Luz Elena Concha del Río² and Miguel Pedroza Seres³

¹ Department of Medical Sciences, Division of Health Sciences, Universidad de Monterrey, Monterrey, Nuevo León, México

² Uveitis Department, Asociación para Evitar la Ceguera en México. I.A.P, Mexico

³ Uveitis and Ocular Immunology Department, Instituto de Oftalmología Conde de Valenciana, México, DF. Clínica de Retina, Guadalajara, J., Mexico

Presumed ocular histoplasmosis syndrome (POHS) is an inflammatory eye disease that has been reported to be associated with systemic fungal infection by *Histoplasma capsulatum* [1]. It is restricted mainly to endemic countries and is mainly seen in the midwest of the United States and where *Histoplasma capsulatum* is endemic [2], although there have been reports of a similar disease from countries that are nonendemic zones for the microorganism [3].

ESSENTIALS OF DIAGNOSIS

POHS is a posterior uveitis, predominantly diagnosed clinically by the observation of characteristic fundus lesions in one or both eyes. The ocular triad of POHS consists in the presence of multiple atrophic choroidal spots (known as *histo spots*) (Fig. 1), peripapillary atrophy (PPA) and maculopathy (Figs. 2-5). Macular lesions are secondary to choroidal neovascularization (CNV) or atrophy and most of the time display a disciform pattern (Figs. 4, 6). Also, one of the key manifestations of POHS is the absence of inflammation in the vitreous. The disease occurs predominately in young adults and linear streaks are described in 5-16% of cases [3, 4]. Initially the disease occurs in one eye, being able to affect the second eye in 9-22% of cases [5, 6].

* Corresponding author Manuel Garza-León: Department of Medical Sciences, Division of Health Sciences, Universidad de Monterrey, Monterrey, Nuevo León, México; Tel: +52 8188824208; Fax: +52 81888242'8; E-mail: manuel@drgarza.mx




Fig. (1). Fundus photographs of a 62-year-old female. Visual acuity was 20/30 in the right eye and 20/25 in the left eye. The anterior segment had no inflammation, there were no vitreous cells. Several chorioretinal scars were observed in the posterior pole and periphery.



Fig. (2). Fundus photograph of the same patient as Fig. (1).




Fig. (3). Fluorescein angiogram of the same patient as Figs. (1 and 2). Dye accumulation due to a fibrous scar is observed adjacent to the optic nerve. Several histo spots may be observed in the periphery.




Fig. (4). OCT of the macula of the same eye as Figs. (1-3). A large area of subretinal fibrosis is observed.

Epiretinal Membrane

Aristides J. Mendoza^{1,2,*}

¹ *Retina Department, Centro Oftalmológico de Valencia (CEOVAL), Valencia, Venezuela*

² *Retina Department, OftalmoSalud, Arequipa, Peru*

The epiretinal membrane (ERM) represents the growth of avascular fibrotic tissue on the surface of the retina in the macular area, which causes loss of vision and distortion of images when it contracts [1].

ERMs can be caused by a variety of eye problems. They are classified as idiopathic when not linked to any other eye disease and usually appear after a posterior vitreous detachment as a result of the formation of retinal tears that release inflammatory cells and pigment epithelial cells deposited at the posterior pole. Secondary ERMs are associated with retinal detachment, intraocular inflammation, trauma and vascular diseases of the retina [2]. There are two types of ERMs that have different clinical presentations: simple and contractile. Simple ERMs are membranes with cellophane-like films on the internal limiting membrane (ILM) with little or no visual symptoms. In general, they are composed mainly of glial cells. On the contrary, tractional ERMs are thicker with contractile properties that cause wrinkling of the retina and are usually accompanied by decreased vision and metamorphopsia. They are composed of glial cells and contractile cells [3], and are also known as “macular puckers” (Fig. 1).

Epiretinal membranes cause macular structural changes such as retinal folds, vascular leakage, macular thickening, cystoid macular edema, pseudohole formation, foveal ectopia, and foveal detachment by tractional forces on the retinal surface [4].

* **Corresponding author Aristides J. Mendoza:** Retina Department, OftalmoSalud, Arequipa, Av Mariscal Benavides No 307, Urb Selva Alegre, Arequipa, Peru; Tel: +51(054)287373; E-mail ampcf@hotmai.com



Fig. (1). Macular pucker secondary to BRVO (Courtesy of Mitzy E. Torres Soriano).

ESSENTIALS OF DIAGNOSIS

Epiretinal membranes typically affect otherwise healthy elderly individuals and are unilateral in approximately 90% of cases. Visual symptoms and decreased visual acuity will depend on the degree of distortion caused in the traction retinal membrane, which can generate a micro detachment of the posterior pole, as well as the presence or absence of macular or perimacular edema. Usually, thin epiretinal membranes don't cause many symptoms. However, in advanced cases, there is a reduction in vision, micropsia, metamorphopsia, Amsler grid distortion and, occasionally, monocular diplopia. Spontaneous separation of an epiretinal macular membrane, although uncommon, can occur [5, 6].

Slit lamp ophthalmoscopy: brightness or abnormal reflectivity in the macular region suggests the presence of an ERM (Fig. 2a). More advanced ERMs can become opaque and thick, and may obscure underlying retinal features (Fig. 1). ERMs cause changes in the retinal architecture with loss of foveal contour as a result of contraction.




Fig. (2). (a) Fundus photograph that shows the typical clinical appearance of an ERM. The membrane adherent to the surface of the retina contracts and the retinal surface appears wrinkled. (b) OCT scan confirms ERM (Courtesy of Mitzy E. Torres Soriano).

In addition to visual acuity testing, the most common clinical tests involve fluorescein angiography and optic coherence tomography (OCT). Fluorescein angiography is moderately helpful, since it can show retinal vascular tortuosity, straightening, and leakage, as well as cystoid macular edema. OCT is the diagnostic method of choice, typically demonstrating a hyperreflective line in the surface of the retina that may be associated to retinal folding, increased macular thickness, cystoid macular edema, traction macular retinal detachment, and both lamellar or macular hole formation (Figs. 2b, 3-6). Amsler grid testing may help quantifying metamorphopsia in eyes with macular distortion [7]. Abnormal macular function has been shown using the electroretinogram [8, 9].

Idiopathic Macular Hole

Luis M. Suarez-Tata^{1,*}, Moravia B. Suarez-Tata¹ and Reinaldo García¹

¹ *Retina & Vitreous Service, Clínica Oftalmológica El Viñedo, Valencia, Venezuela*

Idiopathic macular hole (MH) is an acquired full thickness defect of the retina in the central macula. Macular holes were first described by Knapp in 1869 [1]. They typically occur in the sixth to eighth decade of life with a 3:1 predominance in women. The incidence of bilaterally is 5% to 10%. Tangential vitreoretinal traction (TVT) is the presumed cause of the MH.

ESSENTIALS OF DIAGNOSIS

Visual acuity, depending on the stage and severity of the MH, may be near normal or severely reduced to less than 20/400. Amsler grid will often reveal a central scotoma or metamorphopsia.

Slit-lamp biomicroscopic examination usually shows a round retinal defect that involves the fovea. Several diagnostic maneuvers may be used to find out if the lesion observed in examination is indeed a full-thickness defect (*vs.* a macular *pseudo* hole). If a tall, narrow beam is focused on the lesion, the patient may perceive a break or dent in the beam (the so-called “Watzke-Allen test”). This also may be tested using the aiming beam of a retinal laser photocoagulator.

The gold-standard diagnostic tool is optic coherence tomography (OCT), due to the fact that it is non-invasive, has a very high resolution, allows careful evaluation of retinal structures and the vitreomacular interface.

* **Corresponding author Luis M. Suarez Tata:** Clínica Oftalmológica El Viñedo, Valencia, Venezuela; Tel/Fax: +58 (412) 3474188; E-mail: luismiguel-suarez@gmail.com

It also enables quantitative information such as minimum hole diameter, base diameter and retinal edge thickness [2].

Fluorescein angiography may also be used but has fallen into disuse, since findings are vague (a window defect corresponding to loss of xanthophyll pigment), and compared to OCT has very little sensitivity and specificity.

Classification

Gass described different stages of development of MH (Table 1) [3, 4]. Nowadays, with OCT and the identification of vitreomacular traction and its relationship with MH, the International Vitreomacular Traction Study Group has proposed a new classification based on OCT findings and the status of the vitreomacular interface (Tables 2-4) [5].

Table 1. Stage of development of idiopathic macular hole.

Normal Layer of vitreous cortex lying on internal limiting membrane of retina (Figs. 1 and 2)	
Stage 1A:	Early contraction of outer part of vitreous cortex with foveolar detachment (Fig. 3)
Stage 1B:	Occult hole. Dehiscence of the retinal photoreceptor layer at the umbo with centrifugal retraction of the retinal receptors. Further vitreous contraction and condensation of the prefoveal vitreous cortex with foveal detachment (Figs. 3-5)
Stage 2:	Small perifoveal dehiscence. Small (< 400 μm) (Figs. 6 and 7)
Stage 3:	Larger central full-thickness hole usually accompanied by a rim of retina elevation (>400 μm) (Figs. 8 and 9). The posterior cortical vitreous remains attached. There may be a small operculum overlying the macular hole.
Stage 4:	Macular hole has an associated complete posterior vitreous detachment. These holes are usually large (> 400 μm) (Figs. 10-13)

Based on Gass JD [3, 4].

DIFFERENTIAL DIAGNOSIS

There are several diseases that may resemble MH clinically but have distinct appearances on OCT. Macular pseudohole is an epiretinal membrane that spares the center of the fovea, causing its borders to elevate, clinically resembling a MH. The Watzke-Allen test is negative, and on OCT, the outer retinal layers are spared (Figs. 12-14). Lamellar macular hole is also usually associated to an epiretinal membrane, and on OCT shows an irregular foveal contour with schisis of the

retinal layers in the parafovea, and a preserved photoreceptor layer (Figs. 14-19). Vitreomacular traction syndrome has also to be considered, and actually is believed to play an important role in the pathophysiology of MH. Other differential diagnoses include macular telangiectasia and solar retinopathy [6, 7].



Fig. (1). Fundus photograph showing a normal macula.




Fig. (2). Optical coherence tomography (OCT) image of a normal macula.




Fig. (3). OCT image of a macular hole stage 1-A, showing hyporeflective spaces in the inner and outer retina.

Macular Pseudo-hole

Jose A. Roca^{1,*}, Hugo Luglio² and Daniela Roca¹

¹ *Ophthalmology Department, Clínica Ricardo Palma, Lima-Peru, Peru*

² *Macula D&T, Lima-Peru, Peru*

ESSENTIALS OF DIAGNOSIS

The term “macular pseudo-hole” (MPH) was coined by Allen and Gass in 1976 [1] to describe any foveal lesion that has a biomicroscopic appearance of a full-thickness macular hole (FTMH), but is not. It is usually formed by a centrifugal contraction of an epiretinal tissue (epiretinal membrane) that surrounds but does not cover the foveolar area, making the borders have a more vertical appearance [2].

The patient usually has no complaints, and the visual acuity is normal or nearly normal, ranging from 20/15 to 20/100 (median 20/25) [3]. Because of the good surgical results of true macular holes, it is important to differentiate between a true macular hole and a macular pseudo-hole. The appearance of a true macular hole is different, usually very round, with a halo of marginal detachment surrounding the hole, tiny yellow deposits in its base (within the hole), a translucent operculum in front of some holes, and a zone of hyperfluorescence corresponding to the size of the hole during the early stages of angiography. These characteristics are not seen in a macular pseudo-hole.

Biomicroscopy of a patient with a macular pseudo-hole usually reveals crinkling of the inner retinal surface surrounding the hole in the epiretinal membrane and a punched-out appearance in the area of the hole (Fig. 1) [4]. As the slit beam is

Correspondence: **Corresponding author Jose A. Roca:** Ophthalmology Department, Clínica Ricardo Palma, Torre B, piso 10, San Isidro, Lima-Peru; Tel: +51 (1) 2242224; E-mail: jaroca62@gmail.com

Mitzy E. Torres Soriano, Gerardo García Aguirre, Maximiliano Gordon & Veronica Kon Graversen (Eds.)
All rights reserved-© 2016 Bentham Science Publishers




Fig. (1). Fundus photograph of the left eye, showing a macular pseudohole with an epiretinal membrane.




Fig. (2). OCT of the same patient of Fig. (1), showing a macular pseudo-hole with an epiretinal membrane with a U form fovea and preserved outer retinal layers.



Fig. (3). Autofluorescence of a macular pseudo-hole.




Fig. (4). OCT image of a macular pseudohole showing slight distortion of the foveal contour.

Vitreomacular Traction

Mitzy E. Torres Soriano^{1,2,3,*} and Maximiliano Gordon^{2,3}

¹ *Unidad Oftalmológica “Dr. Torres López”, Centro Médico Cagua, Cagua, Venezuela*

² *Retina Department, Ophthalmology Service, Hospital Provincial del Centenario, Rosario, Santa Fe, Argentina*

³ *Centro de la Visión Gordon-Manavella, Rosario, Argentina*

Vitreomacular Traction Syndrome (VMT) occurs as a result of incomplete posterior vitreous detachment, resulting in persistent vitreous traction on the posterior retina [1].

The prevalence of VMT syndrome is 22.5 per 100,000 population. The annual incidence is 0.6 per 100,000 population. The prevalence and incidence of VMT associated with diabetic retinopathy, diabetic macular edema, age-related macular degeneration, and other macular diseases (concurrent VMT) are much higher [2].

ESSENTIALS OF DIAGNOSIS

Patients may be asymptomatic or present the following symptoms: decreased visual acuity, metamorphopsia, photopsia, and micropsia [1]. Symptoms usually progress gradually [3].

Optical coherence tomography (OCT) allows visualization of the vitreomacular interface and confirms vitreomacular adhesion or traction. Intraretinal cystic changes and foveal detachment can be seen.

Recently, OCT-based anatomic definitions and classifications have been proposed by the International Vitreomacular Traction Study (IVTS) Group to define these entities (Table 1) [4].

* **Corresponding author Mitzy E. Torres Soriano:** Centro de la Visión Gordon - Manavella, Montevideo 763, CP 2000, Rosario - Santa Fe, Argentina; Tel: +54 (0341) 4400239; E-mail: mitzytorres@yahoo.com

Table 1. IVTS classification system for vitreomacular adhesion and vitreomacular traction.

<p>Vitreomacular Adhesion (VMA): Evidence of perifoveal vitreous cortex detachment from the retinal surface. Macular attachment of the vitreous cortex within a 3-mm radius of the fovea. No detectable change in foveal contour or underlying retinal tissues.</p>	<p>Classification <i>By size of attachment area:</i> Focal <1500 µm (Fig. 1) Broad >1500 µm, parallel to RPE and may include areas of dehiscence <i>(By presence of concurrent retinal conditions:)</i> Isolated Concurrent</p>
<p>Vitreomacular Traction (VMT): Evidence of perifoveal vitreous cortex detachment from the retinal surface. Macular attachment of the vitreous cortex within a 3-mm radius of the fovea Association of attachment with distortion of the foveal surface, intraretinal structural changes, and/or elevation of the fovea above the RPE, but no full-thickness interruption of all retinal layers.</p>	<p>Classification <i>By size of attachment area:</i> Focal <1500 µm (Figs. 2, 3 and 5) Broad >1500 µm, parallel to RPE and may include areas of dehiscence (Fig. 4) <i>By presence of concurrent retinal conditions:</i> Isolated Concurrent</p>

Based on International Vitreomacular Traction Study Classification.




Fig. (1). Focal vitreomacular adhesion: partial vitreous detachment.




Fig. (2). Focal vitreomacular traction causing distortion of the foveal contour and separation of retinal layers.




Fig. (3). Focal vitreomacular traction in V pattern, epiretinal membrane and significant distortion of the retinal architecture.

Pseudophakic Cystoid Macular Edema

Andrés Bastien*

Universidad de Buenos Aires-Universidad del Salvador, Retina and Vitreous, Argentina

ESSENTIALS OF DIAGNOSIS

Pseudophakic cystoid macular edema (CME) was first described in 1953 by A. Ray Irvine, Jr., in patients with unexplained visual loss following intracapsular cataract surgery [1]. The cause of the visual loss was identified by Gass and Norton as marked macular edema with a classic perifoveal petalloid pattern of staining and late leakage from the optic nerve on intravenous fluorescein angiography (Figs. 1 - 3) (FA) [2]. The incidence of angiographic CME has decreased with the transition from intracapsular cataract extraction (60%) to extracapsular cataract surgery (20%) and with small-incision phacoemulsification [3, 4]; 20-30% of patients undergoing phacoemulsification have CME on FA [5, 6] and optical coherence tomography (OCT) (Figs. 4 and 5) suggests that it may be found in up to 40% of patients [7]. The majority of patients do not experience visual changes [6, 8]. The incidence is lower with current surgical techniques (0.1% to 2.35%) [9, 10].

Most patients with CME have spontaneous resolution of the edema within 3-4 months [11]. One year after surgery, a small minority of patients (<1%) in the absence of treatment may still have decreased visual acuity from CME [12].

Pathogenesis

Various factors and many presumed mechanisms may be involved in the pathogenesis of CME, including the release of mediators of inflammation such as

* **Corresponding author Andrés Bastien:** Universidad de Buenos Aires-Universidad del Salvador, Retina and Vitreous, Argentina; Tel/Fax: 00541148114482; E-mail: andresbastien@aol.com

prostaglandins, light toxicity, and mechanical irritation [13 - 15]. Inflammatory mediators disrupt the blood-aqueous barrier (BAB) and blood-retinal barrier (BRB), leading to increased vascular permeability resulting in macular edema. Breakdown of the BAB and BRB may be associated with diabetes, glaucoma, and uveitis [16]. Surgical complication of the anterior segment may lead to the release of arachidonic acid from cell membranes, with production of either leukotrienes *via* the lipooxygenase pathway or prostaglandins *via* the cyclooxygenase pathway [13, 14]. These inflammatory biomarkers result in increased retinal vessel permeability and the development of edema. Contraction of the posterior hyaloid as a result of inflammation may lead to mechanical traction onto the perifoveal retinal capillaries and result in CME [15].




Fig. (1). Fluorescein angiography. Perifoveal petaloid staining.




Fig. (2). Fluorescein angiography. Perifoveal petaloid staining.



Fig. (3). Fluorescein angiography with macular late leakage.

Central Serous Chorioretinopathy

Daniel D. Kim¹, Paul Baciu¹ and Michael D. Ober^{1,2,*}

¹ *Department of Ophthalmology, Henry Ford Health Systems, Detroit, MI, USA*

² *Retina Consultants of Michigan, Southfield, MI, USA*

ESSENTIALS OF DIAGNOSIS

Central serous chorioretinopathy (CSC) is an idiopathic disorder characterized by serous detachment of the neurosensory retina. It has an incidence of roughly 6/100,000 individuals [1 - 3]. Affected patients are usually young to middle age adults (ages 25-45), male (5-10:1 male:female ratio), and of “Type A” personality [4 - 6]. The symptoms present unilaterally (60-90% of the time) and patients often complain of blurred central vision and metamorphopsia with a hyperopic shift [1 - 3, 5, 7]. A history of recent psychosocial stressors, or steroid use is often present. Disorders causing elevated levels of catecholamines are known to predispose. Furthermore, pregnancy, phosphodiesterase inhibitors, and illicit drug use have also less commonly been associated with onset of symptoms [2, 3, 6, 8].

Despite decades of study, the precise etiology and pathophysiology remain elusive. Much has been learned, however, through multimodal imaging studies that often yield pathognomonic findings (Fig. 1). Fluorescein angiography (FA) in acute cases reveals a focal leak at the level of the retinal pigment epithelium (RPE) appearing as an expanding hyperfluorescent dot (30% have more than one) sometimes elevating into a smokestack appearance in 10-20% (Figs. 2 and 3). Ultimately, the subretinal fluid pocket can extend inferiorly due to gravity creating descending atrophic tracts, which are best seen with fundus autofluorescence (FAF) [2, 3, 6, 8]. Chronic cases reveal multiple leaks in close

* **Corresponding author Michael D. Ober:** Retina Consultants of Michigan, 29201 Telegraph Road, Suite 606, Southfield, MI 48034, USA; Tel: (248) 356-6473; Fax: (248) 356-6473; E-mail: obermike@gmail.com

proximity with mottled hyper and hypofluorescence of the RPE corresponding to “sick RPE syndrome” [9, 10]. Indocyanine green angiography (ICGA) demonstrates hyperfluorescence in mid-frames (not present early or late) often described as choroidal hyperpermeability (Fig. 4) [2, 3, 6, 8, 11, 12].

As OCT technology has improved, it has become critical for diagnosis. Findings include subretinal fluid, RPE detachments, and retinal atrophy. Less common features include cystoid macular edema or cystoid macular degeneration, which is differentiated by lack of corresponding FA leakage and poor visual potential [2, 5, 8]. While relatively new, visualization of the choroid using enhanced-depth imaging shows marked thickening of the choroid in CSC (Fig. 5), most prominent in zones of choroidal permeability with active angiographic leakage [8, 13].



Fig. (1). CSC Fundus photo showing subretinal fluid causing serous retinal detachment (Photo Credit: Henry Ford Ophthalmic Photography).

Fundus autofluorescence is being used more frequently to image patients with CSC. Over time, a neurosensory detachment leads to an accumulation of lipofuscin from shed photoreceptor outer segments yielding patches of speckled hyperautofluorescence that can become more prominent when subretinal fluid first resolves. Over time, these areas become hypoautofluorescent as noted around

old leaks and chronic descending atrophic tracts [2, 8, 14]. Other diagnostic modalities include multifocal ERG, which shows broad retinal functional disturbances, and abnormal visual field testing, especially on microperimetry, indicating that central visual acuity underestimates the amount of visual impairment [8, 15].




Fig. (2). RPE blowout as imaged by fundus photography (A), early (B) and late (C) fluorescein angiography, autofluorescence (D) and OCT (E) (Photo Credit: Lorrene Santiago).

SUBJECT INDEX**A**

Accelerated-malignant hypertension 68, 73,
74, 76, 77, 78
Acceleration-malignancy 74, 75
Anemia 23, 29, 74
Anterior segment neovascularization 53, 55,
132
Anti-inflammatory drugs 269, 270, 272
Anti-VEGF agents 40, 64, 128, 216, 283
Anti-VEGF treatment 54, 65
Areas, subfoveal 172, 182, 183
Arterial attenuation 84
Arterial hypertension, systemic 67, 99
Arterial macroaneurysms 99, 100
Arterioles, copper wiring of 69, 70, 71, 75
Arterioloized CNVs 179
Arteriovenous crossings, abnormal 69, 70,
71, 73, 79
Asymptomatic VMA patients 258
Autofluorescence 93, 113, 195, 212, 250, 251,
279

B

Best corrected visual acuity (BCVA) 53, 55,
206, 216
Blood-aqueous barrier (BAB) 262
Blood-retinal barrier (BRB) 31, 262
Blood vessels, large choroidal 149, 151, 208
Brilliant blue G (BBG) 232, 246
Bruch's membrane 138, 168, 207, 210, 212,
214, 215, 216
B-wave amplitude 87

C

Capillaries, perifoveal retinal 262
Capillary non-perfusion 49, 61, 62, 64
Cataract surgery, complicated 265, 270
Cells, glial 227
Centrifugal contraction 248, 251
Chorioretinal anastomosis 108, 114, 126
Chorioretinal scars 220, 222

Choroidal infarctions 78
Choroidal neovascularization 39, 105, 108,
168, 193, 201, 208, 211, 213, 214, 219,
251
active 39, 213
subfoveal 121, 208
Choroidal rupture, traumatic 216
Choroidal thickness 282, 283
Chronic arterial hypertension 67, 70, 71, 79
Chronic decompensation 100
Chronic hypertensive arteriolosclerosis 69, 72,
74
Chronic secondary accelerated hypertension
74, 75
Cilioretinal arteries 84, 85, 92, 93
Circular myopic crescent 202, 203
Clinically significant macular edema (CSME)
29, 30, 33, 38
CNV 205, 206, 224
myopic 205, 206, 224
occult 194
Color photo montage 117, 120
Combined fluorescein-indocyanine 179
Cotton-wool spots (CWS) 3, 4, 5, 9, 12, 13,
58, 59, 91, 114, 131
Cystic spaces 31, 264, 268
Cystoid macular edema (CME) 32, 35, 227,
229, 242, 252, 258, 261, 262, 264, 265,
266, 267, 268, 278

D

Decreased visual acuity 91, 100, 103, 104,
228, 254, 261, 268
Dexamethasone intravitreal implants 53
Diabetes mellitus 3, 20, 22, 24, 27, 90, 264
Diabetic retinopathy 3, 5, 13, 15, 18, 26, 29,
31, 36, 41, 64, 74, 86, 94, 127, 134
severe non-proliferative 18
Diabetic retinopathy vitrectomy study (DRVS)
26
Diastolic blood pressure readings 68
Differential diagnosis of CRVO 53
Disciform scar 108, 181, 214, 215, 216
Disease, proliferative 116, 119

Disease progression 183, 216
Domain-optical coherence tomography 36, 37, 39, 41
Drusen 137, 138, 139, 140, 159, 163, 169
 basal laminar 159, 163
 hard 137, 138, 140, 169
 large 137, 149
 medium 137, 139
Drusenoid pigment epithelial detachment (DPED) 140, 146, 158, 161

E

Eales disease and CMV retinitis 14
Early fluorescein angiogram 172, 173, 175, 180
Early hyperfluorescence 139, 163, 172
Early treatment diabetic retinopathy study (ETDRS) 29, 40, 128
Edema resolution 269, 270
Electroretinogram 52, 87, 229
Epiretinal membrane 243, 228, 251, 252,
 located perifoveal 252
 semitransparent perifoveolar 251
 thick 243
 thin 228
Epiretinal membrane peeling 232
Epithelial detachments 8, 178, 187, 193, 194
Extrafoveal chorioretinal scars 223
Exudates, hemorrhages and hard 34, 168
Eyes 130, 132, 182
 affected 130, 132
 contralateral 182

F

Factors, anti-vascular endothelial growth 114, 123, 128, 198, 272
FAF signal 154, 157
Faint stain 141, 144
Features, fundoscopic 44, 47
Female patient 34, 76, 90, 162, 244
 diabetic 34
Female patient complains 101
Fibrinoid necrosis 72, 73
Fibrotic end-stage submacular choroidal neovascularization 211

Flamed-shaped hemorrhages and retinal edema in superior macular area 59
Fluorescein 147, 172, 174, 175, 176
Fluorescein angiogram 3, 5, 6, 119, 121, 122, 133, 134, 139, 174, 176, 189, 213, 221, 222
Fluorescein angiogram (FA) 3, 4, 5, 20, 31, 34, 61, 62, 93, 94, 120, 121, 172, 173, 174
Fluorescein angiography 47, 48, 49, 77, 78, 79, 126, 127, 179, 194, 204, 213, 229, 251, 263
Focal vitreomacular traction 256
Foveal avascular zone, enlarged 20, 121, 122
Foveal contour 182, 183, 235, 242
 irregular 235, 242
 recovery of 182, 183
Foveal depression 183, 230
Foveal detachment 227, 235, 254, 257
FTMH, large 240
Full-thickness macular hole (FTMH) 240, 241, 245, 248, 251
Fundus autofluorescence 86, 93, 113, 210, 277, 278

G

Geographic atrophy (GA) 136, 147, 149, 151, 152, 153, 154, 155, 157, 164
Giant cell arteritis 93, 96, 130
Glaucoma 40, 44, 262, 265

H

Hard exudates and hemorrhages 172
Hemoglobin, mutated 116
Hemorrhages 23, 45, 47, 74, 100, 105, 125, 193, 208, 213
 dense 100
 diffuse retinal 74
 flame-shaped 45, 47
 preretinal 105, 125, 193
 pre-retinal 23
 subfoveal 208, 213
Henry ford ophthalmic photography 278, 280
Heterozygote, double 116
Histoplasma capsulatum 219

Hyperfluorescence 74, 77, 100, 133, 139, 141, 144, 153, 161, 173, 174, 194, 212, 248, 251, 278
 progressive 141, 144
 showing 172, 175, 195
 Hyperfluorescent points, multiple 31, 33
 Hyperreflective 4, 8
 Hyperreflective subretinal material, showing 205
 Hyper-reflective tissue 182, 183
 Hypertension 67, 68, 73, 80
 chronic 68, 73, 80
 primary 67, 68
 Hypertensive patients 67, 68, 80
 Hypertensive subject 67
 Hypofluorescence 34, 49, 61, 146, 161, 278
 Hyporefective spaces, showing 236, 237

I

Idiopathic macular hole 234, 235
 Indocyanine 100, 127, 172, 179, 187, 194, 214, 232, 246, 278
 Inferotemporal BRVO 59, 63, 65
 Inner retinal layers 4, 5, 6, 83, 85, 87, 146, 242
 Interface, vitreomacular 234, 235, 254
 Internal limiting membrane (ILM) 55, 100, 104, 117, 227, 235, 241, 246
 International clinical diabetic retinopathy disease severity scale 12, 13
 International vitreomacular traction stud, (IVTS) 240, 254
 International vitreomacular traction study classification 240, 241, 255
 Intraocular pressure 55, 96, 101, 102, 103, 131, 132
 Intraretinal fluid 54, 65, 177, 182, 183
 accumulation of 177
 recovery of foveal contour and improvement of 182, 183
 showing accumulation of 54, 65
 Intraretinal hemorrhages 3, 4, 13, 18, 45, 60, 95, 101, 102, 117, 134
 diffuse 18
 largest 4
 showing massive 45

Intraretinal hemorrhages and microaneurysms 4
 Intra retinal microvascular abnormalities (IRMAs) 3, 10, 18, 31
 Intraretinal neovascularization 194
 Intravitreal anti-VEGF therapy 182, 183
 Intravitreal injections 40, 53, 105, 198, 271
 IVTS classification system for vitreomacular adhesion 241, 255

L

Laser, subthreshold 105
 Laser photocoagulation 40, 104, 134, 184, 196, 206, 216, 283
 thermal 196, 283
 Late fluorescein angiogram 173, 174, 175, 176, 181
 Leakage 31, 33, 34, 195, 215, 261, 263, 268
 diffuse 31, 195
 late 215, 261, 263, 268
 mild 31, 33, 34
 Left ventricular hypertrophy 68, 71, 77
 Lesions 177, 181, 183, 195, 197
 Hyper reflective 177, 181, 183
 hyperreflective subretinal 195, 197

M

Macroaneurysm 100, 104, 105
 Macula, normal 236
 Macular area 72, 136, 169, 172, 179, 180, 227
 Macular attachment 255
 Macular edema 39, 45, 53, 54, 55, 58, 60, 61, 64, 65, 78, 125, 128, 133, 203, 205, 269, 270, 271
 pseudophakic 39, 269, 270, 271
 Macular hole 235, 241, 242, 243, 245, 248
 full-thickness 241, 245, 248
 lamellar 235, 242, 243
 Macular hole (MH) 114, 232, 234, 235, 236, 238, 240, 241, 244, 246, 248, 251
 Macular hole stage 236, 237, 238
 Macular pseudohole 235, 241, 242, 249, 250, 251
 Macular retinal pigment 84
 Macular thickening 227, 230, 264, 268

Maculopathy 121, 219, 223
Membrane 100, 104, 117, 227, 228, 235
 epiretinal macular 228
 internal limiting 100, 104, 117, 227, 235
Metamorphopsia 107, 168, 202, 216, 223, 227,
 228, 234, 254, 277
Microaneurysms 3, 4, 6, 11, 13, 21, 24, 30, 33,
 107, 127
Microemboli 91
Multiple evanescent white-dot syndrome
 (MEWS) 224
Multiple imaging modalities 119, 120
Myopia 201
 pathologic 201
 pathological 201

N

Neovascularization 53, 114, 130
 angle 53, 130
 pre-retinal 114
Nerve fiber layer 3, 4, 5, 6, 9, 83, 91
Network, vascular 188, 189
Non-clearing vitreous hemorrhage 123, 128
Non-ischemic CRVO 46, 47, 54
Normal autofluorescence 93

O

OCT image 52, 104, 188, 236, 237, 238, 239,
 242, 243, 244, 245, 250, 257
OCT of epiretinal membrane 230
OCT scans 195, 197, 229, 231
Ophthalmic arteries 82, 88
Optical coherence tomography 51, 61, 85, 93,
 104, 126, 140, 205, 210, 236, 254, 261
Optic coherence tomography (OCT) 4, 51, 54,
 61, 63, 141, 146, 177, 178, 182, 183,
 194, 229, 234, 235

P

Panretinal photocoagulation 24, 26, 46, 53, 94,
 134
Papillomacular bundle 92, 93
Perifoveal vitreous cortex detachment 255
Peripapillary PCV 187, 188

Permanent BRAO 90, 91
Photodynamic therapy 128, 184, 190, 197,
 206, 216, 224
Pigment epithelium 108, 203, 238, 239
 irregular retinal 238, 239
Pigment epithelium detachment (PED) 172,
 182, 187, 197, 282
Plexiform layer, outer 4, 8, 264, 268
Posterior hyaloid 18, 259, 262
PPA and extrafoveal chorioretinal scars 223
Progressive glomerulonephritis 74, 77
Pro re nata (PRN) 216
Prostaglandins 262, 265
Pseudoxanthoma elasticum 207, 208, 210, 213
Punctate inner choroidopathy (PIC) 223

R

Radiance study 206
Ranibizumab 40, 53, 64, 183, 216
Rapid progression 154, 157, 158
 indicating 154
RAP lesions 196, 197, 198
Red blood cell (RBC) 116
Reflective material 140, 141, 142, 159
Reflective RPE layer 140, 141
Regions, peripapillary 126, 211, 212
Resolving intraretinal hemorrhage 117
Retina , adjacent 29, 104
Retina 52, 108, 136, 149, 193, 209, 210, 236,
 238, 277
 neurosensory 52, 108, 193, 209, 277
 outer 136, 149, 210, 236, 238
Retinal angiomatous proliferation 193, 195,
 196, 197
Retinal architecture 228, 256
Retinal artery 72, 82, 83, 90, 93, 132
Retinal artery occlusion 82, 86, 93
Retinal choroidal anastomosis (RCA) 194
Retinal damage 68, 246
Retinal detachment 23, 25, 26, 35, 52, 54, 61,
 63, 64, 65, 119, 120, 123, 126, 128, 227,
 229, 258, 278
 associated foveal 258
 serous 35, 52, 54, 61, 63, 65, 278
 tractional 23, 25, 26, 64, 120, 123
 traction macular 229

Retinal edema 58, 59, 72, 76, 85, 100
 Retinal emboli 90, 91
 Retinal folds 227, 230
 Retinal hemorrhages 30, 44, 47, 48, 52, 59,
 132, 127, 131, 194
 characteristic 132
 intra 52
 mid-peripheral 131
 Retinal layers 4, 6, 72, 108, 140, 181, 232,
 235, 236, 238, 241, 245, 255, 256, 257
 deeper 72, 108
 middle 4, 6
 outer 140, 235, 238, 245
 Retinal neovascularization 61, 64, 126, 127
 Retinal pallor 91, 92
 Retinal pigment 105, 109, 213
 Retinal pigment epithelium (RPE) 117, 136,
 140, 141, 143, 146, 147, 193, 207, 208,
 209, 240, 241, 255, 277
 Retinal signs 72, 75
 Retinal stroma 3, 4
 Retinal surface 117, 227, 229, 230, 255, 258
 inner 248, 252
 Retinal telangiectasia 62, 127
 Retinal thickening 29, 30, 112
 Retinal thickness 41, 51, 52, 93, 177, 182,
 183, 197
 increased 51, 52, 183
 showing decreased 182, 183
 showing increased 177
 Retinal tissue 88, 251
 Retinal traction 35, 105
 Retinal transparency 109, 111
 Retinal vein 45, 47, 58, 80
 Retinal vein occlusion 44, 58, 74, 121, 134,
 267
 Retinal vessels 108, 133, 193, 202
 Retinitis pigmentosa 210, 265
 Retinopathy 121, 125, 134
 Retinovascular diseases 18
 Right eye 19, 20, 24, 34, 36, 131, 158, 159,
 160, 162, 169, 214, 215, 220, 222
 RPE atrophy 108, 136, 146, 154, 213, 214
 RPE cells 139, 147, 154

S

Scanning laser ophthalmoscope (SLO) 251
 Scotomas 91, 162, 216, 234, 251
 Serous chorioretinopathy 182, 251, 277
 Serous PED 194, 196, 198
 Showing epiretinal membrane 230
 Showing retinal hemorrhages 126
 Showing subretinal fluid 195, 278
 Sickle cell disease 14, 95, 116, 121, 210
 Sickle cell trait 116
 Skin, histoplasmin 223
 Small drusen 137
 Soft drusen 136, 138, 139, 140, 141, 142, 148,
 154, 156, 164
 confluent 156, 164
 Spectral domain optical coherence
 tomography (SDOCT) 121, 230
 Spots 3, 58, 59, 91, 114, 117, 118, 131
 cotton-wool 3, 58, 59, 91, 114, 131
 iridescent 117, 118
 Stage-II RAP lesions 194, 198
 Staining 47, 48, 50, 262, 263, 268
 perifoveal petalloid 262, 263, 268
 vessel wall 47, 48, 50
 Stenosis, carotid 130
 Subfoveal CNV 169, 170, 171, 224
 Subfoveal fluid 264, 268
 Subhyaloid hemorrhage 18, 78, 103
 Submacular hemorrhage 169, 170, 171
 large 169
 massive 171
 Subretinal fibrosis 105, 171, 172, 180, 181,
 221
 Subretinal fluid 52, 54, 65, 112, 168, 172, 178,
 182, 183, 194, 213, 278, 281, 282
 Subretinal hemorrhage 105, 169, 170, 174,
 176, 180, 187, 211
 associated 170
 massive 176
 small 169
 Subretinal neovascularization 194, 202, 209
 classic 209

Subretinal space 117, 194, 212
Superotemporal, subretinal choroidal
neovascularization 222
Superotemporal arcade 20, 24, 94

T

Tangential vitreoretinal traction (TVT) 234
Telangiectasias 125, 126, 196, 232, 266
parafoveal 196, 232
Temporal macula 122
Thickness macular hole 108, 238, 239, 240,
244, 245, 258
Topical combination 270, 271
Topical non-steroidal 269, 270
Tortuosity, vascular 117, 229
Traction, vitreo macular 266, 267
Transit time, arteriovenous 47, 48
Treatment of CRVO 53
Triamcinolone 53, 55, 64
Trypan blue (TB) 232, 246

V

Vascular diseases 58, 121, 130, 134, 227
Vascular endothelial growth factor (VEGF)
31, 40, 114, 123, 128, 198, 224, 272
Vascular occlusions 73, 126, 127, 266
Vascular retinal diseases 44

Vein occlusions 13, 14, 18, 39, 73, 93, 134,
265
Venous beading 3, 10, 11, 12, 18, 24
severe 11
Vessels 6, 59, 60, 91, 93, 94, 108, 109, 111,
179
affected 91, 93, 94
normal 6, 108
right angle 109, 111
sclerotic 59, 60
showing thick 179
VH eyes 26
Visual acuity 54, 64, 65, 100, 101, 102, 103,
105, 107, 159, 160, 232, 234, 244, 246
Visual field defects 58, 93, 95, 96
Visual fields 83, 87, 162
Visual loss 29, 91, 96, 119, 125, 146, 261
Vitrectomy 25, 55, 132, 244, 259
Vitreomacular Adhesion (VMA) 240, 241,
254, 255, 258
Vitreomacular traction syndrome 232, 236,
254
Vitreous cells 220, 224
Vitreous cortex 235, 255
Vitreous hemorrhage (VH) 23, 61, 64, 117,
119, 122, 126, 131

W

Watzke-Allen test 234, 235
Wool spots, multiple cotton 74, 75



Mitzy E. Torres Soriano

Dr. Mitzy E. Torres Soriano graduated with honors in medicine at the University of Carabobo, Maracay, Venezuela in 2001. Then in 2003 she began her postgraduate studies in Ophthalmology in Hospital Miguel Pérez Carreño (Caracas, Venezuela) where she also served as Chief Resident, and completed them in 2005. From 2006 to 2008, she did a fellowship in Retina and Vitreous in Asociación para evitar la Ceguera. Hospital Dr. Luis Sánchez Bulnes, in Mexico. She dedicates her clinical practice to the medical and surgical treatment of retinal and vitreous diseases.

She has taken many courses and attended numerous congresses on ophthalmology, and has also written various articles and book chapters. She provides review services to several science international journals about ophthalmology and contributes in retinal clinical research.



Gerardo García-Aguirre

Dr. Gerardo García-Aguirre graduated magna cum laude, obtaining his medical degree at the School of Medicine, Tecnológico de Monterrey, in Monterrey, Mexico in 2002, and his residency in Ophthalmology and Retina fellowship at Asociación para Evitar la Ceguera en México, in Mexico City. In 2008 he became an attending physician at the same hospital. He is author or coauthor of over 30 papers, 15 book chapters and one book in the field of ophthalmology.



Maximiliano Gordon

Dr. Maximiliano Gordon graduated in medicine from Universidad Nacional de Rosario, Rosario, Argentina, in 1999. He did an ophthalmology residency at Centro de la Vision, located in Rosario, between 2000 and 2002, and a fellowship in Retina and Vitreous at the Asociación para Evitar la Ceguera, at Hospital Luis Sanchez Bulnes, located in Mexico City, Mexico, between 2006 and 2008.

With more than 10 years of experience in clinical and surgical management of diseases of the retina and vitreous, he currently works as a retina specialist in Centro de la Vision Gordon-Manavella and as instructor in the residency program of the Retina department of Hospital Provincial del Centenario, in Rosario.



Veronica Kon Graversen

Dr. Veronica Kon Graversen attended Catholic University of Santiago de Guayaquil, School of Medicine where she graduated Summa Cum Laude. She was then accepted into one of the most prestigious ophthalmology training programs in Latin America at the Ophthalmology Institute Conde de Valenciana in Mexico city. She then completed a two-year Retina and Vitreous surgical fellowship at the Association to Prevent Blindness in Mexico (APEC), Luis Sanchez Bulnes Hospital, under the preceptorship of Hugo Quiroz Mercado.

Dr. Kon Graversen completed a second ophthalmology residency program at the University of North Carolina at Chapel Hill, where she also served as Chief Resident. She is eligible to be board certified in Ophthalmology. She has published numerous articles in peer-reviewed journals and has lectured at multiple international meetings. She recently moved to Denmark with her husband and is affiliated with Glostrup Hospital.